Home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants

Information

  • Patent Grant
  • 9844461
  • Patent Number
    9,844,461
  • Date Filed
    Tuesday, January 25, 2011
    13 years ago
  • Date Issued
    Tuesday, December 19, 2017
    6 years ago
Abstract
Home-use applicators for non-invasively removing heat from subcutaneous, lipid-rich cells via phase change coolants, and associated devices, systems and methods. A device in accordance with a particular embodiment includes an applicator releasably positionable in thermal communication with human skin, and a coolant vessel having a coolant. The device further includes a heat transfer conduit operatively coupled to the applicator and housing a heat transfer fluid that is isolated from fluid contact with the coolant. A heat exchanger is operatively coupled between the coolant vessel and the heat transfer conduit to transfer heat between the heat transfer fluid and the coolant, and a fluid driver is operatively coupled to the heat transfer conduit to direct the heat transfer fluid between the applicator and the heat exchanger.
Description
TECHNICAL FIELD

The present application relates generally to home-use applicators for non-invasively removing heat from subcutaneous lipid-rich cells via phase change coolants, and associated devices, systems and methods. In particular, several embodiments are directed to devices that a user may easily recharge or regenerate using a conventional commercial, clinical, institutional or domestic freezer.


BACKGROUND

Excess body fat, or adipose tissue, may be present in various locations of the body, including, for example, the thighs, buttocks, abdomen, knees, back, face, arms, chin, and other areas. Moreover, excess adipose tissue is thought to magnify the unattractive appearance of cellulite, which forms when subcutaneous fat protrudes into the dermis and creates dimples where the skin is attached to underlying structural fibrous strands. Cellulite and excessive amounts of adipose tissue are often considered to be unappealing. Moreover, significant health risks may be associated with higher amounts of excess body fat.


A variety of methods have been used to treat individuals having excess body fat and, in many instances, non-invasive removal of excess subcutaneous adipose tissue can eliminate unnecessary recovery time and discomfort associated with invasive procedures such as liposuction. Conventional non-invasive treatments for removing excess body fat typically include topical agents, weight-loss drugs, regular exercise, dieting or a combination of these treatments. One drawback of these treatments is that they may not be effective or even possible under certain circumstances. For example, when a person is physically injured or ill, regular exercise may not be an option. Similarly, weight-loss drugs or topical agents are not an option when they cause an allergic or other negative reaction. Furthermore, fat loss in selective areas of a person's body often cannot be achieved using general or systemic weight-loss methods.


Other methods designed to reduce subcutaneous adipose tissue include laser-assisted liposuction and mesotherapy. Newer non-invasive methods include applying radiant energy to subcutaneous lipid-rich cells via, e.g., radio frequency and/or light energy, such as is described in U.S. Patent Publication No. 2006/0036300 and U.S. Pat. No. 5,143,063, or via, e.g., high intensity focused ultrasound (HIFU) radiation such as is described in U.S. Pat. Nos. 7,258,674 and 7,347,855. In contrast, methods and devices for non-invasively reducing subcutaneous adipose tissue by cooling are disclosed in U.S. Pat. No. 7,367,341 entitled “METHODS AND DEVICES FOR SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al. and U.S. Patent Publication No. 2005/0251120 entitled “METHODS AND DEVICES FOR DETECTION AND CONTROL OF SELECTIVE DISRUPTION OF FATTY TISSUE BY CONTROLLED COOLING” to Anderson et al., the entire disclosures of which are incorporated herein by reference.





BRIEF DESCRIPTION OF THE DRAWINGS

Many features of the present technology are illustrated in simplified, schematic and/or partially schematic formats in the following Figures to avoid obscuring significant technology features. Many features are not drawn to scale so as to more clearly illustrate these features.



FIG. 1 is a partially schematic, partially cut-away illustration of a cooling device having a coolant vessel and heat exchanger configured in accordance with an embodiment of the disclosure.



FIG. 2 is a partially schematic, partially cut-away illustration of a particular embodiment of the device shown in FIG. 1.



FIG. 3 is a partially schematic illustration of a device having an overall arrangement generally similar to that shown in FIG. 1, configured in accordance with still another embodiment of the disclosure.



FIG. 4 is a partially schematic illustration of a device having a heat exchanger and a removable coolant vessel configured in accordance with another embodiment of the disclosure.



FIG. 5A is a partially schematic, enlarged illustration of an embodiment of the coolant vessel and heat exchanger shown in FIG. 4.



FIG. 5B is a partially schematic, cross-sectional illustration of the heat exchanger and coolant vessel taken substantially along line 5B-5B of FIG. 5A.



FIG. 6A is a partially schematic, partially cut-away illustration of a coolant vessel and heat exchanger configured in accordance with another embodiment of the disclosure.



FIG. 6B is a partially schematic, cross-sectional illustration of an embodiment of the heat exchanger and coolant vessel, taken substantially along line 6B-6B of FIG. 6A.



FIG. 7 is a partially schematic illustration of a device having a coolant vessel and heat exchanger that are separable from an applicator in accordance with yet another embodiment of the disclosure.



FIG. 8 is a partially schematic illustration of a portion of the coolant vessel and heat exchanger, taken substantially along line 8-8 of FIG. 7.



FIG. 9 is a partially schematic, cross-sectional illustration of an applicator having non-elastic and elastic materials arranged in accordance with an embodiment of the disclosure.



FIG. 10 is a partially schematic, cross-sectional illustration of an applicator having an internal support structure in accordance with an embodiment of the disclosure.



FIG. 11 is an enlarged illustration of a portion of the applicator shown in FIG. 10.





DETAILED DESCRIPTION
1. Overview

Several examples of devices, systems and methods for cooling subcutaneous adipose tissue in accordance with the presently disclosed technology are described below. Although the following description provides many specific details of the following examples in a manner sufficient to enable a person skilled in the relevant art to practice, make and use them, several of the details and advantages described below may not be necessary to practice certain examples and methods of the technology. Additionally, the technology may include other examples and methods that are within the scope of the claims but are not described here in detail.


References throughout this specification to “one example,” “an example,” “one embodiment” or “an embodiment” mean that a particular feature, structure, or characteristic described in connection with the example is included in at least one example of the present technology. Thus, the occurrences of the phrases “in one example,” “in an example,” “one embodiment” or “an embodiment” in various places throughout this specification are not necessarily all referring to the same example. Furthermore, the particular features, structures, routines, steps or characteristics may be combined in any suitable manner in one or more examples of the technology. The headings provided herein are for convenience only and are not intended to limit or interpret the scope or meaning of the claimed technology.


Certain embodiments of the technology described below may take the form of computer-executable instructions, including routines executed by a programmable computer or controller. Those skilled in the relevant art will appreciate that the technology can be practiced on computer or controller systems other than those shown and described below. The technology can be embodied in a special-purpose computer, controller, or data processor that is specifically programmed, configured or constructed to perform one or more of the computer-executable instructions described below. Accordingly, the terms “computer” and “controller” as generally used herein refer to any data processor and can include internet appliances, hand-held devices, multi-processor systems, programmable consumer electronics, network computers, mini computers, and the like. The technology can also be practiced in distributed environments where tasks or modules are performed by remote processing devices that are linked through a communications network. Aspects of the technology described below may be stored or distributed on computer-readable media, including magnetic or optically readable or removable computer discs as well was media distributed electronically over networks. In particular embodiments, data structures and transmissions of data particular to aspects of the technology are also encompassed within the scope of the present technology. The present technology encompasses both methods of programming computer-readable media to perform particular steps, as well as executing the steps.


One embodiment of a cooling device for cooling subcutaneous lipid-rich cells in a human includes an applicator that is releasably positionable in thermal communication with human skin. The device further includes a coolant vessel having a coolant and a heat transfer conduit having a heat transfer fluid that is isolated from fluid contact with the coolant. A heat exchanger is operatively coupled between the coolant vessel and heat transfer conduit to transfer heat between the heat transfer fluid and the coolant, and a fluid driver is operatively coupled to the heat transfer conduit to direct the heat transfer fluid between the applicator and the heat exchanger.


In a further particular embodiment, the coolant has a liquid/solid phase transition temperature greater than the liquid/solid phase transition temperature of the heat transfer fluid. The heat exchanger is positioned within the coolant vessel and includes a heat exchanger conduit that, together with the heat transfer conduit and the applicator, form a sealed, closed-loop path for the heat transfer fluid. Accordingly, the entire device can be placed in a freezer (e.g., a domestic freezer) to freeze the coolant in preparation for treating lipid-rich cells in a human. In other embodiments, only selected components of the device are removable to freeze or otherwise cool the coolant.


A method for cooling human tissue in accordance with a particular embodiment of the disclosure includes releasably attaching an applicator to a human, and removing heat from subcutaneous lipid-rich tissue of the human via the applicator to selectively reduce lipid-rich cells of the tissue (e.g., via the body's reaction to cooling). The heat is removed by directing a chilled heat transfer fluid to applicator and transferring absorbed heat from the heat transfer fluid to a coolant. In particular embodiments, the coolant can remain solid, remain liquid or change phase from a solid to a liquid as it receives heat from the heat transfer fluid. The method still further includes re-cooling the coolant. Selected methods in accordance with another embodiment of the disclosure include removing the heat by directing a chilled heat transfer fluid into a flexible envelope and through a porous internal support structure within the envelope, while the porous internal structure at least restricts fluid pressure in the envelope from (a) bulging the envelope outwardly, or (b) collapsing the internal structure, or (c) both (a) and (b). Still another method includes directing the chilled heat transfer fluid into an applicator, between two flexible portions of the applicator, each having a different elasticity.


Without being bound by theory, the selective effect of cooling on lipid-rich cells is believed to result in, for example, membrane disruption, cell shrinkage, disabling, damaging, destroying, removing, killing or other methods of lipid-rich cell alteration. Such alteration is believed to stem from one or more mechanisms acting alone or in combination. It is thought that such mechanism(s) trigger an apoptotic cascade, which is believed to be the dominant form of lipid-rich cell death by non-invasive cooling. In any of these embodiments, the effect of tissue cooling is to selectively reduce lipid-rich cells.


Apoptosis, also referred to as “programmed cell death”, is a genetically-induced death mechanism by which cells self-destruct without incurring damage to surrounding tissues. An ordered series of biochemical events induce cells to morphologically change. These changes include cellular blebbing, loss of cell membrane asymmetry and attachment, cell shrinkage, chromatin condensation and chromosomal DNA fragmentation. Injury via an external stimulus, such as cold exposure, is one mechanism that can induce cellular apoptosis in cells. Nagle, W. A., Soloff, B. L., Moss, A. J. Jr., Henle, K. J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990).


One aspect of apoptosis, in contrast to cellular necrosis (a traumatic form of cell death causing local inflammation), is that apoptotic cells express and display phagocytic markers on the surface of the cell membrane, thus marking the cells for phagocytosis by macrophages. As a result, phagocytes can engulf and remove the dying cells (e.g., the lipid-rich cells) without eliciting an immune response. Temperatures that elicit these apoptotic events in lipid-rich cells may contribute to long-lasting and/or permanent reduction and reshaping of subcutaneous adipose tissue.


One mechanism of apoptotic lipid-rich cell death by cooling is believed to involve localized crystallization of lipids within the adipocytes at temperatures that do not induce crystallization in non-lipid-rich cells. The crystallized lipids selectively may injure these cells, inducing apoptosis (and may also induce necrotic death if the crystallized lipids damage or rupture the bi-lipid membrane of the adipocyte). Another mechanism of injury involves the lipid phase transition of those lipids within the cell's bi-lipid membrane, which results in membrane disruption or disfunction, thereby inducing apoptosis. This mechanism is well-documented for many cell types and may be active when adipocytes, or lipid-rich cells, are cooled. Mazur, P., “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970); Quinn, P. J., “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147 (1985); Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003). Another mechanism of injury may involve a disfunction of ion transfer pumps across the cellular membrane to maintain desired concentrations of ions such as potassium (K+) or sodium (Na+). An ion imbalance across the cell membrane may result from lipid phase transition of lipids within the cell's bi-lipid membrane or by another mechanism, thereby inducing apoptosis. Other yet-to-be-understood apoptotic mechanisms may exist, based on the relative sensitivity to cooling of lipid-rich cells compared to non-lipid rich cells.


In addition to the apoptotic mechanisms involved in lipid-rich cell death, local cold exposure is also believed to induce lipolysis (i.e., fat metabolism) of lipid-rich cells and has been shown to enhance existing lipolysis which serves to further increase the reduction in subcutaneous lipid-rich cells. Vallerand, A. L., Zamecnik. J., Jones, P. J. H., Jacobs, I. “Cold Stress Increases Lipolysis, FFA Ra and TG/FFA Cycling in Humans” Aviation, Space and Environmental Medicine 70, 42-50 (1999).


One expected advantage of the foregoing techniques is that the subcutaneous lipid-rich cells can be reduced generally without collateral damage to non-lipid-rich cells in the same region. In general, lipid-rich cells can be affected at low temperatures that do not affect non-lipid-rich cells. As a result, lipid-rich cells, such as those associated with cellulite, can be affected while other cells in the same region are generally not damaged even though the non-lipid-rich cells at the surface may be subjected to even lower temperatures than those to which the lipid-rich cells are exposed.


2. Representative Devices and Methods that Include Applicators, Coolant Vessels, and Heat Exchangers Arranged as a Single Unit


FIG. 1 is a partially schematic, partially cut-away illustration of a device 100 having an applicator 120 operatively coupled to a coolant vessel 140 to cool human tissue 110. In particular, the device 100 is configured to cool a subcutaneous, lipid-rich tissue 112, without damaging the overlying dermis 111, generally in the manner described above. The applicator 120 is coupled to the coolant vessel 140 by a heat transfer conduit 150 that carries a heat transfer fluid 155. Accordingly, the heat transfer conduit 150 includes a supply portion 151a that directs the heat transfer fluid 155 to the applicator 120, and a return portion 151b that receives heat transfer fluid 155 exiting the applicator 120. The heat transfer fluid 155 is propelled through the heat transfer conduit 150 by a fluid driver 170, e.g., a pump or other suitable device. The heat transfer conduit 150 is typically insulated to prevent the ambient environment from heating the heat transfer fluid 155. Other elements of the device (aside from the cooling surface of the applicator 120 in contact with the tissue 110) are also insulated from the ambient environment to prevent heat loss and frost formation.


The heat transfer conduit 150 is connected to a heat exchanger 160 having a heat exchanger conduit (e.g., tubing) 161 that is positioned within or at least partially within the coolant vessel 140. The coolant vessel 140 contains a coolant 141 that is in close thermal contact with the heat exchanger 160, but is isolated from direct fluid contact with the heat transfer fluid 155 contained within the heat exchanger tubing 161. Accordingly, the heat exchanger 160 facilitates heat transfer between the heat transfer fluid 155 and the coolant 141, while preventing these fluids from mixing. As a result, the coolant 141 can be selected to have a composition different than that of the heat transfer fluid 155. In particular embodiments, the coolant 141 can be selected to have a phase transition temperature (from liquid/gel to solid) that is less than normal body temperature (about 37° C.) and in particular embodiments, in the range of from about 37° C. to about −20° C., or about 25° C. to about −20° C., or about 0° C. to about −12° C., or about −3° C. to about −6° C., to present a constant temperature environment to the heat transfer fluid 155 as the coolant 141 transitions from a solid to a liquid/gel. The heat transfer fluid 155 in such embodiments has a phase transition temperature that is less than that of the coolant 141. Accordingly, the heat transfer fluid 155 remains in a fluid state even when the coolant 141 or a portion of the coolant 141 is in a solid state. As a result, the heat transfer fluid 155 can flow within the heat transfer conduit 150 to convey heat away from the human tissue 110 even when the coolant 141 is frozen or at least partially frozen.


In operation, the device 100 can be prepared for use by placing the major components (e.g., the applicator 120, the heat transfer conduit 150, the heat exchanger 160 and the coolant vessel 140), as a unit, in a suitably cold environment. In a particular embodiment, the cold environment includes a freezer (e.g., a domestic freezer), in which the temperature typically ranges from about −10° C. to about −20° C., sufficient to freeze the coolant 141. After the coolant 141 is frozen, the device 100 can be removed from the freezer or other cold environment, as a unit, and the applicator 120 can be attached to the human tissue 110 using a cuff or other suitable attachment device (e.g., having a Velcro® closure, a buckle, or other releasable feature). Optionally, the user can apply a lotion between the applicator 120 and the skin to facilitate heat transfer and/or provide a moisturizing or other cosmetic effect. Whether or not the user applies a lotion or another intermediate constituent, the applicator 120 is positioned in thermal communication with the user's skin, so as to effectively remove heat from the lipid-rich tissue 112. The fluid driver 170 is then activated to drive the heat transfer fluid 155 through the heat transfer conduit 150, thus transferring heat from the subcutaneous lipid-rich tissue 112 to the frozen coolant 141 via the heat exchanger 160. As the coolant 141 melts, the temperature within the coolant vessel 140 remains approximately constant so as to provide a constant or nearly constant heat transfer fluid temperature to the human tissue 110. After the human tissue 110 has been cooled for an appropriate period of time, causing some or all of the coolant 141 to melt, the device 100 can be removed as a unit from the human tissue 110, as indicated by arrow A, and the coolant 141 can be re-frozen by placing the device 100 in the freezer. Accordingly, the cooling capacity of the coolant vessel 140 can be readily recharged or regenerated prior to a subsequent treatment process. The appropriate tissue-cooling period of time can be controlled by properly selecting the cooling capacity of the coolant 141, or via a controller and/or sensor, as described in further detail later with reference to FIG. 2.


In particular embodiments described above with reference to FIG. 1 and below with reference to FIGS. 2-8, the coolant 141 changes phase as it is heated by the heat transfer fluid 155, and then changes back again when it is cooled. In other embodiments, the coolant 141 can be heated and cooled without undergoing phase changes. For example, the coolant 141 can remain in a solid phase throughout both the heating and cooling processes, or can remain in a liquid phase throughout both processes. In such cases, the cooling process (whether it takes place in a freezer or other environment) does not freeze the coolant. When the coolant 141 remains a solid, its phase transition temperature is above that of the heat transfer fluid. When the coolant 141 remains a liquid, its phase transition temperature can be above, below, or equal to that of the heat transfer fluid 155. In such cases, the heat transfer fluid 155 and the coolant 141 can have different or identical compositions, while remaining isolated from direct fluid contact with each other.



FIG. 2 is a partially schematic, partially cut-away illustration of an embodiment of the device 100 that operates in accordance with the general principles described above with reference to FIG. 1. Accordingly, the device 100 shown in FIG. 2 includes an applicator 120 and a coolant vessel 140 thermally connected to the applicator 120 via a heat exchanger 160 and a heat transfer conduit 150.


One characteristic of the device 100 shown in both FIG. 1 and FIG. 2 is that the when the applicator 120 is first placed against the human tissue 110, the heat transfer fluid 155 in the heat transfer conduit 150 and the applicator 120 will be at or approximately at the temperature of the cold environment in which the device 100 was placed. In at least some cases, this temperature may be uncomfortably low. Accordingly, the device 100 and associated methods can include features for reducing the likelihood that the user will encounter a potentially detrimental effect or uncomfortably cold sensation when first using the device 100. In a particular embodiment, the device 100 can include a heater 152 positioned to heat the heat transfer fluid 155 entering the applicator 120 via the supply portion 151a. This arrangement can increase the temperature of the heat transfer fluid 155 by at least an amount sufficient to reduce the user's discomfort and/or provide a safe and efficacious treatment. In a further particular aspect of this embodiment, the device 100 can be configured to shunt the heat transfer fluid 155 away from the heat exchanger 160 while the heat transfer fluid temperature is initially elevated. This arrangement can avoid unnecessarily melting the coolant 141 before treatment begins. Accordingly, the device 100 can include a shunt channel 153 connected between the supply portion 151a and the return portion 151b in parallel with the heat exchanger 160 to bypass the heat exchanger 160. One or more shunt valves 154 (two are shown in FIG. 2) are positioned to regulate flow through the shunt channel 153, e.g., to open or partially open the shunt channel 153 during initial startup, and then close or partially close the shunt channel 153 after the temperature of the applicator 120 has been elevated by a sufficient amount.


The device 100 can include a controller 180 to control the heater 152, the shunt valves 154, and/or other features of the device 100. For example, in a particular embodiment, the controller 180 includes a microprocessor 183 having a timer component 184. When the device 100 is initially powered (e.g., by activating the fluid driver 170), the microprocessor 183 can automatically open the shunt channel 153 via the shunt valves 154, and activate the heater 152. The heater 152 and the shunt channel 153 can remain in this configuration for a predetermined time, after which the microprocessor 153 automatically issues control signals deactivating the heater 152 and closing the shunt channel 153. Accordingly, the timer component 184 operates as a sensor by sensing the passage of time during which the heater 152 is actively heating the heat transfer fluid 155. In other embodiments described further below, one or more sensors can detect other characteristics associated with the device 100.


In a particular embodiment, the microprocessor 183 can direct the control signals 182 based on inputs 181 received from one or more temperature sensors 186. For example, the device 100 can include a first temperature sensor 186a positioned at the applicator 120. The microprocessor 183 can automatically activate the heater 152 and the shunt channel 153 until the first temperature sensor 186a indicates a temperature suitable for placing the applicator 120 against the human tissue 110. The device 100 can include a second temperature sensor 186b located at the coolant vessel 140 (e.g., the center of the coolant 141). The microprocessor 183 can accordingly direct control signals 182 that activate the fluid driver 170 for as long as the second temperature sensor 186b indicates a constant and/or suitably low temperature. When the second temperature sensor 186b identifies a temperature rise (indicating that the coolant 141 has completely melted), the microprocessor 183 can automatically deactivate the fluid driver 170. If the coolant 141 is not selected to change phase during heating and cooling, the micro-processor 183 can deactivate the fluid driver 170 when the temperature of the coolant 141 exceeds a threshold temperature. The controller 180 can include an output device 185 that indicates the operational modes or states of the device 100. For example, the output device 185 can display visual signals (e.g., via different colored LEDs) and/or aural signals (e.g., via an audio speaker) to signify when the applicator 120 is ready to be applied to the human tissue 110, when the treatment program is over, and/or when temperatures or other characteristics of any of the device components are outside pre-selected bounds.


In yet another embodiment, the controller 180 can direct a simplified process for handling the initial temperature of the heat transfer fluid 155. In particular, the controller 180 can monitor the temperature signal provided by the first temperature sensor 186a, without activating the fluid driver 170, and without the need for the heater 152 or the shunt channel 153. Instead, the controller 180 can generate an output (presented by the output device 185) when the ambient conditions cause the heat transfer fluid 155 to rise to an acceptable temperature, as detected by the first temperature sensor 186a. The user can optionally accelerate this process by applying heat to the applicator 120 and/or the heat transfer conduit 150 via an external heat source. An advantage of this approach is that it can be simpler than the integrated heater 152 described above. Conversely, the heater 152 (under the direction of the controller 180) can be more reliable and quicker, at least in part because the heater 152 is positioned within the insulation provided around the heat transfer conduit 150 and other device components.


The device 100 can include a variety of features configured to enhance uniform heat distribution and heat transfer. For example, the heat exchanger 160 can include fins 165 on the heat exchanger tubing 161 to increase the surface area available to transfer heat between the heat transfer fluid 155 and the coolant 141. The coolant vessel 140 can also include a first agitator 101a that distributes the melting coolant 141 within the coolant vessel 140 to provide for a more uniform temperature and heat transfer rate within the vessel 140. In one embodiment, the first agitator 101a can include a magnetically driven device, and can be magnetically coupled to a first actuator motor 102a positioned outside the coolant vessel 140. Accordingly, the agitator 101a can operate without the need for a sealed drive shaft penetrating into the coolant vessel 140. A similar arrangement can be used at the applicator 120. In particular, the applicator 120 can include a second agitator 101b driven by a second actuator motor 102b to distribute the heat transfer fluid 155 uniformly within the applicator 120. Suitably positioned internal fluid channels can be used in addition to or in lieu of the second agitator 101b to uniformly distribute the heat transfer fluid 155 in the applicator 120. A representative device that includes such features is a Model No. 10240 pad, available from Breg Polar Care (bregpolarcare.com). The actuator motors 102a, 102b can be operatively coupled to a power cord 173, which also provides power to the fluid driver 170 and the heater 152. In other embodiments, the device 100 can include other elements that agitate and/or distribute the fluid in the applicator 120 and/or the coolant vessel 140. Such elements can include liquid jets, shaft-driven stirrers, pistons and/or other devices that move the solid and/or liquid portion of the coolant 141 within the coolant vessel 140, and/or actuators that vibrate, shake, tip or otherwise move the coolant vessel 140 itself or heat exchanger 160 within the coolant vessel.


As noted above, the applicator 120, the heat transfer conduit 150, the heat exchanger 160, and the coolant vessel 140 can be moved as a unit between the target tissue 110 and a freezer or other cold environment prior to and after treatment. In a particular embodiment, the remaining components or elements of the device 100 shown in FIG. 2 can also be placed in the freezer. For example, when the fluid driver 170 includes a pump 171 driven by a pump motor 172, these components (along with the controller 180) can also be placed in the freezer. In other embodiments, one or more of these components may be removed prior to placing the rest of the device 100 in the freezer. For example, the power cord 173 can be removed from the motor 172 and other system components at a junction B1 as indicated by arrow B. In another embodiment, the pump motor 172 can be removed from the device 100 at a junction Cl as indicated by arrow C. For example, the pump motor 172 can be magnetically coupled to the pump 171, generally in the manner of the stirrers described above to make connecting and disconnecting the motor 172 easier. In still another aspect of this embodiment, the controller 180 and/or components of the controller 180 can be carried by the motor 172 and can accordingly be removed from the device 100 along with the motor 172.


Certain features described above in the context of a processor-based automatic control system can, in other embodiments, operate without a processor, or can operate manually. For example, the shunt valves 154 can include thermostatic radiator values, or similar valves that have an integrated temperature sensor (e.g., a mechanical thermostat) that autonomously drives the valve without the need for a processor. In other embodiments, the coolant 141 can change color as it undergoes its phase change, which can eliminate the need for the second temperature sensor 186b. In one aspect of this embodiment, the coolant vessel 140 is transparent, allowing the user to readily see both when the coolant 141 is frozen and when the coolant 141 has melted. In the event the device 100 loses coolant 141 over the course of time, the coolant vessel 140 can include a fill/drain port 142. In a particular aspect of this embodiment, the fill/drain port 142 can have a removable plug 148 that is transparent, in addition to or in lieu of the coolant vessel 140 being transparent. Similarly, the heat transfer fluid 155 can include constituents that change color when the heat transfer fluid attains a temperature that is no longer suitable for properly chilling the tissue 110. The applicator 120 and/or the heat transfer conduit 150 (or portions thereof) can be made transparent to allow the user to easily determine when this temperature threshold has been exceeded.


Both the coolant 141 and the heat transfer fluid 155 are selected to be highly thermally conductive. Suitable constituents for the coolant 141 include water in combination with propylene glycol, ethylene glycol, glycerin, ethanol, isopropyl alcohol, hydroxyethyl cellulose, salt, and/or other constituents. In at least some embodiments, the same constituents can be used for the heat transfer fluid 155, but the ratios of the constituents (and therefore the overall composition of the heat transfer fluid) are selected to produce a lower liquid/solid phase transition temperature. Both the heat transfer fluid 155 and the coolant 141 can be selected to have high heat conductivity and low toxicity in case of a leak. Both can include an anti-microbial agent to restrict or prevent algae formulation and/or propagation of other undesirable life forms. The coolant 141 can be selected to have a high heat capacity to better absorb heat from the heat transfer fluid 155. The heat transfer fluid 155 can have a relatively low heat capacity so that it readily heats up when the heater 152 is activated. The heat transfer fluid 155 can also be selected to have a low viscosity at operating temperatures to facilitate flow through the heat transfer conduit 150, the heat exchanger 160 and the applicator 120. In any of these embodiments the coolant vessel 140 in which the coolant 141 is disposed can be flexible and elastic, and/or can include a vent or other feature to accommodate volume changes as the coolant 141 changes phase.



FIG. 3 is a partially schematic, isometric illustration of an embodiment of the device 100 described above with reference to FIG. 2. As shown in FIG. 3, the applicator 120 has a generally flexible configuration, allowing it to conform to the shape of the tissue to which it is applied. An attachment device 123 releaseably attaches the applicator 120 to the tissue and can accordingly include a strap (e.g. Velcro), a cuff (e.g., generally similar to a blood pressure cuff) or another suitable device. The coolant vessel 140 is housed in a coolant vessel housing 143 that is in turn attached to or otherwise includes the support structure 121. The support structure 121 can be at least partially flexible so that when it is attached to the applicator 120, it does not overly inhibit the ability of the applicator 120 to conform to the human tissue. In one embodiment, the support structure 121 and the coolant vessel housing 143 can be supported relative to the applicator 120 with standoffs. In another embodiment, an optional foam or other flexible layer (e.g. an inflatable air bladder) 122 can be positioned between the support structure 121 and the applicator 120 to further facilitate the ability of the applicator 120 to flex relative to the coolant vessel housing 143.


In one aspect of an embodiment shown in FIG. 3, the power cord 173 can be releasably attached directly to the pump motor 172, thus allowing the power cord 173 to be removed before the device 100 is placed in the freezer. The power cord 173 can be connected directly to an AC outlet, and can include a DC converter if the pump motor 172 is a DC motor. If the pump motor 172 is coupled to a rechargeable battery located within the housing 143, the power cord 173 can be used to recharge the battery.


In another aspect of this embodiment, the pump motor 172 itself can be removed from the coolant vessel housing 143, along with the power cord 173, generally in the manner described above with reference to FIG. 2. In still a further particular aspect of this embodiment, the controller 180 (not visible in FIG. 3) and associated output device 185 can be carried by the pump motor 172 and can accordingly be readily removed from the coolant vessel housing 143 along with the pump motor 172.


One feature of particular embodiments of the device 100 described above with reference to the FIGS. 1-3 is that the applicator 120, the coolant vessel 140, the heat exchanger 160, and the heat transfer conduit 150 can be configured as an inseparable unit (at least during normal use—components may be separated by an authorized servicer if necessary during a maintenance or repair process). Accordingly, these components form a sealed, closed-loop path for the heat transfer fluid 155. An advantage of this feature is that it is simple to use. In particular, the user can place the entire device 100 (or at least the above components) in the freezer or other cold environment until the coolant 141 is frozen, and can remove the entire device 100 as a unit from the freezer or other cold environment prior to cooling the target tissue. Because the arrangement is simple to use, it can be particularly suitable for home use. Because it does not include removable components (in certain embodiments) or separable fluid connections, it is expected to be more robust than systems that do include such features. Because the coolant 141 has a fixed liquid/solid phase transition temperature, the device 100 can easily control the temperature of the heat transfer fluid 155 with a reduced level of active control, and the device 100 can be thermally recharged in any environment having a temperature less than the phase transition temperature.


Another feature of particular embodiments of the device 100 described above is that the volume of heat transfer fluid 155 contained in the system can be made relatively low by using short lengths and/or small diameters for the heat transfer conduit 150 and the heat exchanger tubing 161, and a low (e.g., thin) profile for the applicator 120. Accordingly, the coolant 141 can more quickly cool the heat transfer fluid 155 and the entirety of the effective heat transfer surface of the applicator 120. Having a low thermal mass for the heat transfer fluid 155 will also reduce the amount of time and/or energy required to elevate the temperature of the applicator 120 to a comfortable level after the device 100 has been removed from the freezer.


Still another feature of particular embodiments of the device 100 described above is that the unitary arrangement of the device is expected to produce a compact size and therefore low mass. These features in turn can make it easier to position the device in a freezer (e.g., a domestic freezer), and can make the device more comfortable and convenient to wear during use.


Yet another feature of at least some of the foregoing embodiments is that the simplicity of the device can reduce manufacturing costs and therefore the costs to the user. In at least some instances, the device need not include the serviceable component features described above because the device may be cheaper to replace than repair. The device can include an automated lock-out or shut-down feature that activates after a predetermined number of uses to prevent use beyond an expected period of threshold efficacy or useful life.


3. Representative Devices and Methods that Include Separable Coolant Vessels


FIG. 4 is a partially schematic, partially cut-away illustration of an embodiment of a device 400 having a user-removable or separable coolant vessel 440, unlike the configurations described above with reference to FIGS. 1-3. In particular, the device 400 can include a heat exchanger 460 having a heat exchanger conduit (e.g., tubing) 461 positioned external to the coolant vessel 440, allowing the coolant vessel 440 to be removed from the device 400 (as indicated by arrow D) for thermal recharging or regeneration. Accordingly, the coolant vessel 440 can be placed in a cold environment (e.g., a freezer) to re-cool (e.g., re-freeze) the coolant 141, without placing the entire device 400 in the cold environment. This arrangement may be suitable for applications in which freezer space is limited and thus placing only the coolant vessel 440 in the freezer is advantageous. As a result, certain aspects of the device 400 can be simpler than the device 100 described above with reference to FIGS. 1-3. For example, the heat transfer conduit 150 is not cooled along with the coolant vessel 440 and accordingly the need for the heater 152 and/or shunt channel 153 and shunt valves 154 described above with reference to FIG. 2 can be eliminated. Conversely, an advantage of the arrangement described above with reference to FIGS. 1-3 is that the interface between heat exchanger tubing 161 and the coolant vessel 140 need not be disturbed when the coolant vessel 140 is chilled. As described further below with reference to FIGS. 5A-6B, certain aspects of the device 400 are designed to mitigate the potential impact of detaching and reattaching the heat exchanger 460 and the coolant vessel 440.



FIG. 5A is an enlarged, partially schematic illustration of an embodiment of the coolant vessel 440 and the heat exchanger 460 in which the heat exchanger tubing 461 is positioned around the outside of the coolant vessel 440. In particular, the heat exchanger tubing 461 can have a serpentine shape extending upwardly and downwardly along the longitudinal axis of the coolant vessel 440. The heat transfer fluid 155 passes through the heat transfer tubing 461 as indicated by arrows E. To remove the coolant vessel 440 from the heat exchanger 460, the user pulls the coolant vessel 440 upwardly as indicated by arrow D in FIG. 5A. The heat exchanger tubing 461 can be “springy” and can accordingly be resiliently biased inwardly toward the coolant vessel 440 to releasably secure the coolant vessel 440 in position, and to provide intimate thermal contact between the heat exchanger tubing 461 and the exterior surface of the coolant vessel 440. This feature can also promote a “scrubbing” mechanical contact between the heat exchanger tubing 461 and the exterior surface of the coolant vessel 440 to remove frost build-up or other residue to ensure good thermal contact as these components are connected. Further details of the foregoing arrangement are described below with reference to FIG. 5B.



FIG. 5B is a partially schematic, cross-sectional illustration of the heat exchanger 460 and the coolant vessel 440, taken substantially along line 5B-5B of FIG. 5A. As shown in FIG. 5B, the coolant vessel 440 can have an outer surface with a series of recesses 449, each of which is sized and positioned to receive a portion of the heat exchanger tubing 461. The exterior surface of the coolant vessel 440 can include a first thermally conductive surface 462a that is in intimate thermal and physical contact with a corresponding second thermally conductive surface 462b of the heat exchanger tubing 461. Accordingly, this arrangement can readily transfer heat between the heat transfer fluid 155 within the heat exchanger tubing 461, and the coolant 141 within the coolant vessel 440. The coolant vessel 440 can include features for uniformly distributing the liquid portion of the coolant 141 (e.g., agitators) in a manner generally similar to that described above with reference to FIG. 2.



FIGS. 6A and 6B illustrate another arrangement of a coolant vessel 640 that is removably attached to a corresponding heat exchanger 660 in accordance with another embodiment of the technology. In one aspect of this embodiment, the coolant vessel 640 includes multiple vertically extending blind channels 644 defined at least in part by a thermally conductive channel wall 645. The heat exchanger 660 includes thermally conductive heat exchanger tubing 661 that directs the heat transfer fluid 155 into and out of the blind channels 644. In particular, the heat exchanger tubing 661 can include supply sections 664a that extend into the blind channels 644 and are coupled to a supply manifold 663a. The heat exchanger tubing 661 can further include corresponding return sections 664b that also extend into each of the blind channels 644 and are coupled to a return manifold 663b. In a particular embodiment, the return sections 664b are located annularly inwardly within the corresponding supply sections 664a. Accordingly, the heat transfer fluid enters the supply sections 664a, rises within the blind channels 664 and then descends through the return sections 664b, as indicated by arrows E. The coolant vessel 640 is removed from the heat exchanger 660 by pulling it upwardly away from the heat exchanger 660 as indicated by arrow D, and is replaced by placing it downwardly over the heat exchanger 660, with the blind channels 644 aligned with the corresponding supply sections 664a. The blind channels 644 and the corresponding supply sections 664a can be tapered and/or otherwise biased into contact with each other to promote thermal contact and to facilitate mechanically scraping frost from surfaces of either element.



FIG. 6B is a partially schematic, cross-sectional illustration of the coolant vessel 640 and the heat exchanger 660, taken substantially along line 6B-6B of FIG. 6A. As shown in FIG. 6B, the blind channels 664 include thermally conductive channel walls 665 that are in intimate thermal contact with the outer surfaces of the supply sections 664a. Arrows E indicate the radially inward path of the heat transfer fluid 155 as it moves from the supply sections 664a to the return sections 664b.


4. Representative Devices and Methods that Include Separable Coolant Vessels and Heat Exchangers


FIG. 7 is a partially schematic, partially cut-away illustration of a device 700 having a releasable coupling 756 between a heat exchanger 760 and a coolant vessel 740 on one hand, and the heat transfer conduit 150 on the other. Accordingly, the releasable coupling 756 can include a supply coupling 757a at the supply portion 151a of the heat transfer conduit 150, and a return coupling 757b at the return portion 151b of the heat transfer conduit 150. The couplings 757a, 757b can include any suitable fluid-tight, easily releasable and reattachable elements. For example, the couplings 757a, 757b can include quick-release couplings generally similar to those used for intravenous fluid connections.


One feature of an embodiment shown in FIG. 7 is that, like the embodiments described above with reference to FIGS. 4-6B, the entire device 700 need not be placed in the freezer or other cold environment to re-solidify or otherwise re-cool the coolant 141. In addition, the device 700 does not require that the thermal connection between the heat exchanger 760 and the coolant vessel 740 be disturbed in order to recharge the coolant vessel 740. Conversely, an advantage of the arrangements described above with reference to FIGS. 1-6B is that they do not require connecting and disconnecting fluid conduits.



FIG. 8 is a partially schematic, cross-sectional illustration of a portion of the heat exchanger 760 and the coolant vessel 740, taken substantially along line 8-8 of FIG. 7. As shown in FIG. 8, the coolant vessel 740 can include a vessel wall 746 having an insulative portion 747a over a portion of its surface, and a conductive portion 747b in areas adjacent to the heat exchanger tubing 761. For example, the insulative portion 747a can include a material such as a plastic that has a low thermal conductivity to prevent or at least restrict heat transfer to the coolant vessel 740 except as it is received from the heat exchanger tubing 761. The conductive portion 747b can include copper or another highly thermally conductive material that readily transfers heat between the coolant 141 and the heat exchanger tubing 761, which can also include copper or another highly thermally conductive material. The heat exchanger tubing 761 can be welded to or otherwise intimately bonded to the conductive portion 747b in a way that provides high thermal conductivity between the two. In other embodiments, the heat exchanger tubing 761 can take the form of a channel that is integrally formed with the conductive portion 747b, e.g., in a casting process.


When the coolant 141 is selected to undergo a phase change during operation, it can include a solid component 141a generally positioned away from the vessel wall 746 once the coolant 141 begins to melt, and a liquid component 141b generally in contact with the inner surface of the vessel wall 746 and conductive portion o the vessel wall 747b. As described above, the coolant vessel 740 can include an agitator or other device to enhance the uniform distribution of heat transfer within the coolant vessel 740 by circulating the liquid component 141b, moving the solid component 141a, and/or vibrating or otherwise moving the coolant vessel 740.


5. Representative Applicators and Associated Methods


FIGS. 9-11 illustrate particular features of applicators that may form a portion of any of the devices described above with reference to FIGS. 1-8. In other embodiments, these applicators may be used with devices other than those expressly shown and described above with reference to FIGS. 1-8. The size and shape of the applicator can be selected based on the user's physiology and the location on the user's body to which the applicator will be attached.



FIG. 9 illustrates an applicator 920 that includes an envelope 924 having an entry port 928a coupled to a heat transfer fluid supply portion 151a, and an exit port 928b coupled to a return portion 151b. The envelope 924 can include a flexible first portion 925 in contact with the human tissue 110, and a flexible second portion 926 facing away from the human tissue 110. The flexible first portion 925 can be attached to the flexible second portion 926 at corresponding bonds 927 formed by an adhesive, thermal welding, or other suitable process. The first portion 925 has a first elasticity, and the second portion 926 has a second elasticity less than the first elasticity. Accordingly, the second portion 926 can, in at least some embodiments, be non-elastic. As used herein, the term “non-elastic” applies to a material that does not stretch, or stretches by only an insignificant amount when the applicator 920 is subjected to normal operating pressures. The term “elastic” as used herein applies to a material that does stretch when the applicator is subjected to normal operating pressures provided by the attachment of the device to the patient and/or heat transfer fluid 155. Because the first portion 925 is more elastic than the second portion 926, it can readily conform to the local shape of the human tissue 110. In particular, the first portion 925 can conform to the underlying tissue 110 without forming creases 930 (shown in dotted lines in FIG. 9), which form in some existing devices and can interfere with skin/applicator thermal contact and/or internal flow within the applicator 920. As a result, the first portion 925 is more likely to remain in close thermal contact with the human tissue 110 and can therefore more efficiently transfer heat away from the tissue 110. The second portion 926 can flex in a manner that accommodates the contour of the human tissue 110, without stretching at all, or without stretching in a manner that might cause the envelope to bulge outwardly away from the tissue 110 (e.g., at the ends of the applicator 920) and thereby reduce the degree of thermal contact between the envelope 924 (and more particularly, the heat transfer fluid 155) and the tissue 110.


In particular embodiments, the second portion 926 can include polyethylene, polypropylene, nylon, vinyl, and/or another suitable plastic film. The first portion 925 can include latex rubber, nitrile, polyisoprene and/or urethane, and/or another suitable elastomeric material. An optional elastic mesh 929 can be positioned adjacent to the first portion 925 (or the entire envelope 924), and can include an elastic nylon, rubber and/or other suitable elastic material. The mesh 929 can prevent the first portion 925 from undergoing excessive wear and/or bulging during handling. It can accordingly be strong, but thin enough to avoid significantly interfering with the heat transfer process between the applicator 920 and the tissue 110.


In a particular embodiment, the applicator 920 can also include a flexible support structure 921 that provides additional support for the envelope 924, without inhibiting the ability of the envelope 924 to conform to the tissue 110. The support structure 921 can also function as the releasable coupling (e.g., a cuff) securing the applicator 920 to the tissue 110. In any of these embodiments, the support structure 921 can have a pre-formed shape (e.g., a downwardly-facing concave shape) and can be resiliently biased toward the pre-formed shape. Accordingly, the applicator 920 can more readily conform to a convex tissue surface. In particular embodiments, a family of applicators having different shapes can be coupled to a similar type of overall cooling device to provide for system commonality and interchangeability.



FIG. 10 is a partially schematic, cross-sectional illustration of an applicator 1020 having an envelope 1024, an external support structure 1021a generally similar to that described above with reference to FIG. 9, and an internal support structure 1021b located within the envelope 1024. The internal support structure 1021b can be porous, e.g., 50% porosity or higher in some embodiments, and in particular embodiments, in the range of from about 75% porosity to about 95% porosity. Accordingly, the internal support structure 1021b can diffuse the heat transfer fluid 155 throughout the envelope 1024 from an entry port 1028a to an exit port 1028b, without overly restricting the flow of the heat transfer fluid 155. The particular porosity value selected for the internal support structure 1021b can depend on factors that include the viscosity and/or flow rate of the heat transfer fluid 155. In a particular embodiment, the internal support structure 1021b can include a porous matrix material having one or multiple layers 1031 (three are shown in FIG. 10 for purposes of illustration) that can slide relative to each other, as indicated by arrows F. In a further particular embodiment, the internal support structure 1021b is attached to the inner surfaces of the envelope 1024 to prevent the envelope from overly stretching. The envelope 1024 can also include spaced-apart connections 1035 (e.g., stitches or perforated panels) that extend from the envelope upper surface through the internal support structure 1021b to the envelope lower surface to prevent or restrict the envelope 1024 from ballooning when pressurized with the heat transfer fluid 155 while allowing the layers 1031 to slide laterally relative to each other. Accordingly, when the applicator 1020 is coupled to an upstream fluid driver 1070a, the pressure exerted by the incoming heat transfer fluid 155 on the envelope 1024 will be less likely to expand the envelope 1024.


The internal support structure 1021b can resist buckling, in addition to or in lieu of resisting bulging or ballooning. For example, the internal support structure 1021b can have a high enough buckling strength so that when the applicator 1020 is coupled to a downstream fluid driver 1070b, the envelope 1024 will not collapse upon itself due to external, ambient pressure (e.g., to the point that it inhibits the flow of heat transfer fluid 155) when the heat transfer fluid 155 is withdrawn through the exit port 1028b. In particular embodiments, the heat transfer fluid 155 may be withdrawn via a pressure that is up to about 2 psi below the pressure outside the envelope 1024. In other embodiments, the foregoing pressure differential can be up to about 5 psi or 10 psi without the envelope 1024 collapsing on itself. This will help keep the envelope from ballooning due to positive internal pressure. Another advantage of the downstream fluid driver 1070b is that if the envelope 1024 is inadvertently punctured, the downstream fluid driver 1070b will suck air through the puncture, while the upstream fluid driver 1070a will continue to pump heat transfer fluid 155 through such a puncture.



FIG. 11 is a partially schematic, enlarged illustration of a portion of the applicator 1020 circled in FIG. 10. As shown in FIG. 11, the internal support structure 1021b can include small pores 1034 distributed throughout the structure. At the interface with the tissue 110, the pores can form a distributed arrangement of generally hemispherical dimples. When the envelope 1024 includes a material that is not elastic, the material will tend to crease when folded over a convex portion of the tissue 110. The pores 1034 are small enough so that they accommodate or receive small “microcreases” 1033 that can form along the surface of the envelope 1024. Unlike the creases 930 described above with reference to FIG. 9, the microcreases 1033 are very small and accordingly do not significantly inhibit the internal flow within the applicator and do not significantly disrupt the uniformity of the heat transfer between the heat transfer fluid 155 within the envelope 1024, and the tissue 110 outside the envelope 1024. In effect, the microcreases 1033 can distribute the creasing effect of the envelope material over a larger area that reduces the overall impact of the effect on fluid flow and heat transfer. In particular embodiments, the microcreases 1033 can have a generally hemispherical shape that is pre-set into the envelope material using a thermoset process. In other embodiments, the shape and/or formation process of the microcreases 1033 can be different. In still another embodiment, the entire portion of the envelope 1024 in contact with the patient tissue can have a pre-set or pre-formed shape (e.g., a hemispherical or other concave shape) that is maintained as the envelope is placed in contact with the patient tissue;


In a particular embodiment, the internal support structure 1021b can include a TN Blue non-abrasive non-woven polyester pad available from Glit/Microtron. This material can be made in multiple layers (e.g., two layers, each 0.35 of an inch thick) encased in a polyether-polyurethane film envelope 1024 having a thickness of 0.006-0.012 inches. The internal support structure 1021b, which is already porous due to the fibrous make-up of the material, can be even further perforated with a hole pattern, producing small diameter holes spaced uniformly spaced apart, and oriented generally perpendicular to the major surfaces of the envelope 1024. These holes can facilitate bending the internal support structure 1021b to conform to convex and/or concave shapes. It is expected that the relatively thin overall dimensions of the resulting applicator 1020 (e.g., from about 0.25 inch to about 0.50 inch) will allow the applicator 1020 to readily conform to the human anatomy. The low flow impedance of the internal support structure 1021b is expected to allow flow rates of approximately 0.1 to 5 liters per minute, suitable for adequately cooling the adjacent tissue. In addition, the three-dimensional nature of the fibrous, porous structure can facilitate a uniform distribution of the heat transfer fluid 155 within the applicator 1020, producing a more uniform treatment of the adjacent tissue 110.


The porosity of the internal support structure 1021b can vary from one portion of the applicator 1020 to another, and/or can vary depending upon the local flow direction desired for the heat transfer fluid 155. For example, the porosity of the internal support structure 1021b can be selected to enhance heat transfer from the tissue in the peripheral areas of the applicator 1020, e.g., to account for the expected increase in heat transfer losses to the ambient environment in these areas. The porosity can be altered by adjusting the number and/or size of the pores within the internal support structure 1021b, as well as the spatial orientation of the pores.


From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but that various modifications can be made without deviating from the technology. For example, the devices described above can include components that provide mechanical energy to create a vibratory, massage and/or pulsatile effect in addition to cooling the subcutaneous tissue. Representative components are described in U.S. Pat. No. 7,367,341 and in commonly assigned U.S. Patent Publication No. 2008/0287839, both of which are incorporated herein by reference. While certain features of the devices described above make them particularly suitable for home use, such features do not preclude the devices from being used in hospital or clinical office settings. In such embodiments, the devices or portions of the devices can be cooled in commercial, clinical or institutional freezers and/or coolers. The shapes, sizes and compositions of many of the components described above can be different than those disclosed above so long as they provide the same or generally similar functionalities. For example, the conduits and tubing described above can have other shapes or arrangements that nevertheless effectively convey fluid. The fluid driver can be operatively coupled to the heat transfer conduit without being directly connected to the heat transfer conduit, e.g., by being connected to the heat exchanger that conveys the heat transfer fluid, or by being connected to the applicator. The controller can implement control schemes other than those specifically described above, and/or can be coupled to sensors other than those specifically described above (e.g., pressure sensors) in addition to or in lieu of temperature and time sensors, to detect changes associated with the cooling device. The controller can in some cases accept user inputs, though in most cases, the controller can operate autonomously to simplify the use of the device. As discussed above, the coolant in some embodiments can go through a phase change during heating and cooling, so that the cooling process freezes or solidifies the coolant. In other embodiments for which no phase change occurs, the cooling process does not freeze or solidify the coolant.


Certain aspects of the technology described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, the applicators described above in the content of FIGS. 9-11 can be used with any of the devices described above with reference to FIGS. 1-8. The thermal connections between the heat exchanger tubing and the coolant vessel described in the content of FIG. 8 can be applied to the arrangement shown and described in the content of FIGS. 1-3. The heaters and flow agitators described in the context of certain embodiments can be eliminated in other embodiments. Further, while advantages associated with certain embodiments of the technology have been described within the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the present disclosure. Accordingly, the present disclosure and associated technology can encompass other embodiments not expressly shown or described herein.

Claims
  • 1. A cooling device for cooling subcutaneous lipid-rich cells in a human, comprising: an applicator releasably positionable against human skin, the applicator including:a flexible, fluid-tight envelope having an entry port, an exit port, a fluid chamber, and first and second oppositely-facing internal surfaces positioned on opposite sides of the fluid chamber; anda porous internal structure positioned within the envelope between the entry port and the exit port, positioned directly between the first and second internal surfaces of the envelope, and positioned throughout substantially the entire fluid chamber, the internal structure including multiple layers of fibrous material positioned face-to-face such that the layers of fibrous material slidably contact one another along substantially an entire length of the porous internal structure when the flexible, fluid-tight envelope is completely filled with a pressurized fluid, the internal structure:(a) having a buckling strength sufficient to prevent the envelope from collapsing on itself when the outlet port is exposed to a pressure below a pressure external to the envelope, and(b) being attached to an inner surface of the envelope to at least restrict the envelope from bulging when a pressurized fluid is applied to an entry port.
  • 2. The device of claim 1 wherein the internal structure has a buckling strength sufficient to prevent the envelope from collapsing on itself when the outlet port is exposed to a pressure of up to 2 psi below a pressure external to the envelope.
  • 3. The device of claim 1 wherein the internal structure has a buckling strength sufficient to prevent the envelope from collapsing on itself when the outlet port is exposed to a pressure of up to 5 psi below a pressure external to the envelope.
  • 4. A cooling device for cooling subcutaneous lipid-rich cells in a human, comprising: an applicator releasably positionable against human skin, the applicator including:a flexible, fluid-tight envelope having an entry port, an exit port, a fluid chamber, and first and second oppositely-facing internal surfaces positioned on opposite sides of the fluid chamber; anda porous internal structure positioned within the envelope between the entry port and the exit port, positioned directly between the first and second internal surfaces of the envelope, and positioned throughout substantially the entire fluid chamber, the internal structure including layers of fibrous material in a face-to-face arrangement such that the layers of fibrous material slidably contact one another over substantially an entire length of the porous internal structure when the flexible, fluid-tight envelope is filled with a pressurized fluid, the porous internal structure:(a) having a buckling strength sufficient to prevent the envelope from collapsing on itself when the outlet port is exposed to a pressure below a pressure external to the envelope, wherein the internal structure has a buckling strength sufficient to prevent the envelope from collapsing on itself when the outlet port is exposed to a pressure of up to 10 psi below a pressure external to the envelope, and(b) being attached to an inner surface of the envelope to at least restrict the envelope from bulging when a pressurized fluid is applied to an entry port.
  • 5. A cooling device for cooling subcutaneous lipid-rich cells in a human, comprising: an applicator releasably positionable against human skin, the applicator including:a flexible, fluid-tight envelope having an entry port, an exit port, and a fluid holding chamber; anda porous internal structure positioned within the fluid holding chamber and located between the entry port and the exit port, wherein the internal structure includes multiple layers of fibrous material positioned face-to-face such that the layers of fibrous material slidably contact one another along substantially an entire length of the porous internal structure when the envelope is completely filled with a pressurized fluid, the internal structure:(a) having a buckling strength sufficient to prevent the envelope from collapsing on itself when the outlet port is exposed to a pressure below a pressure external to the envelope, and(b) being attached to an inner surface of the envelope to at least restrict the envelope from bulging when the pressurized fluid is applied to an entry port.
  • 6. The device of claim 1 wherein the applicator further comprises attachment elements extending from the first internal surface to the second internal surface.
  • 7. The device of claim 1, further comprising: a heat exchanger operably coupled to the applicator; anda pump having an inlet coupled to the exit port of the applicator to draw fluid from the applicator, and an outlet upstream of the heat exchanger.
  • 8. The device of claim 1, further comprising: a heat exchanger operably coupled to the applicator; anda pump having an outlet coupled to the entry port of the applicator to pump fluid into the applicator, and an inlet downstream of the heat exchanger.
  • 9. The device of claim 1 wherein the envelope includes: a first portion comprising a flexible first material positioned to be placed against the skin and having a first elasticity; anda second portion sealably connected to the first portion, the second portion comprising a flexible second material facing away from the first portion and having a second elasticity less that the first elasticity, at least one of the first and second portions being movable relative to the other to accommodate the pressurized fluid therebetween.
  • 10. The device of claim 1 wherein a portion of the envelope that is positionable against human skin has a pre-formed concave shape.
  • 11. The cooling device of claim 1, further comprising: a fluid driver fluidically coupled to the entry port, the exit port, and a heat exchanger, wherein the fluid driver is configured to cause fluid that has been cooled by the heat exchanger to flow through the porous internal structure to remove heat from the subcutaneous lipid-rich cells via the applicator in an amount sufficient to selectively reduce the subcutaneous lipid-rich cells.
  • 12. The cooling device of claim 1 wherein the fluid flows through the porous internal structure to diffuse through the fluid chamber of the envelope.
  • 13. The cooling device of claim 1 wherein the porous internal structure is physically coupled to the first internal surface and is physically coupled to the second internal surface.
  • 14. The cooling device of claim 1 wherein the porous internal structure has a porosity of 50% or higher.
  • 15. A cooling device for cooling subcutaneous lipid-rich cells in a human, comprising: an applicator configured to be positioned against human skin, the applicator including:a flexible, fluid-tight envelope having an entry port, an exit port, and first and second oppositely-facing internal surfaces; andan internal structure contained within the envelope and positioned directly between the first and second internal surfaces, the internal structure occupying a majority of a volume of a chamber in the envelope and configured to diffuse fluid through the chamber of the envelope, the internal structure including layers of fibrous material positioned face-to-face such that the layers of fibrous material slidably contact one another along substantially an entire length of the porous internal structure when the envelope is completely filled with a pressurized fluid, the internal structure:(a) having a sufficient buckling strength and being positioned to prevent contact between opposing inner surfaces of the envelope when the outlet port is exposed to a pressure below a pressure external to the envelope and fluid flows through the internal structure, and(b) being attached to an inner surface of the envelope to at least restrict the envelope from bulging when fluid applied to an entry port is pressurized.
  • 16. A cooling device for cooling subcutaneous lipid-rich cells in a human, comprising: an applicator configured to be positioned against human skin, the applicator including: a flexible, fluid-tight envelope having an entry port, an exit port, and first and second oppositely-facing internal surfaces; andan internal structure contained within the envelope and positioned directly between the first and second internal surfaces, the internal structure occupying a majority of a volume of a chamber in the envelope and configured to diffuse fluid through the chamber of the envelope, the internal structure: (a) having a sufficient buckling strength and being positioned to prevent contact between opposing inner surfaces of the envelope when the outlet port is exposed to a pressure below a pressure external to the envelope and fluid flows through the internal structure, and(b) being attached to an inner surface of the envelope to at least restrict the envelope from bulging when fluid applied to an entry port is pressurized,a heat exchanger; anda fluid driver fluidically coupled to the entry port, the exit port, and the heat exchanger, wherein the internal structure is porous, and wherein the fluid driver is configured to cause fluid that has been cooled by the heat exchanger to travel through the porous internal structure and to remove heat from subcutaneous lipid-rich tissue in a human via the applicator in an amount sufficient to selectively reduce the subcutaneous lipid-rich cells.
  • 17. The cooling device of claim 15 wherein the internal structure is physically connected to the first internal surface and physically coupled to the second internal surface.
  • 18. The cooling device of claim 15 wherein the internal structure has a porosity of 50% or higher.
  • 19. The cooling device of claim 15 wherein the internal structure is located throughout most of a chamber of the envelope when the envelope is filled with fluid.
  • 20. The cooling device of claim 15 wherein the internal structure extends across most of a distance between the entry port and the exit port when the envelope is filled with fluid.
  • 21. The cooling device of claim 1 wherein the internal structure is positioned throughout most of the fluid chamber of the envelope such that the internal structure distributes fluid flowing through the fluid chamber to promote uniform cooling of tissue adjacent the applicator.
  • 22. The cooling device of claim 1 wherein the internal structure is positioned throughout most of the fluid chamber of the envelope when the envelope is filled with fluid.
  • 23. A cooling device for cooling subcutaneous lipid-rich cells in a human, comprising: an applicator releasably positionable against human skin, the applicator including:a flexible, fluid-tight envelope having an entry port, an exit port, a first surface, and a second surface; anda porous internal structure positioned within the envelope between the entry port and the exit port and directly between the first and second surfaces, wherein the internal structure includes multiple layers of fibrous material positioned face-to-face such that the layers of fibrous material slidably contact each other along substantially an entire length of the porous internal structure when the envelope is filled with fluid, and wherein at least one of the multiple layers is slidable relative to the envelope when the envelope is filled with the fluid, the internal structure having a buckling strength sufficient to prevent the envelope from collapsing on itself when the outlet port is exposed to a pressure below a pressure external to the envelope.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to the following U.S. Provisional Patent Applications, each of which is incorporated herein by reference: 61/298,175, filed Jan. 25, 2010 and 61/354,615, filed Jun. 14, 2010. To the extent that the materials in the foregoing references and/or any other references incorporated herein by reference conflict with the present disclosure, the present disclosure controls.

US Referenced Citations (612)
Number Name Date Kind
681806 Mignault Sep 1901 A
889810 Robinson Jun 1908 A
2516491 Swastek Jul 1950 A
2726658 Chessey Dec 1955 A
2766619 Tribus et al. Oct 1956 A
2851602 Cramwinckel et al. Sep 1958 A
3093135 Hirschhorn Jun 1963 A
3132688 Nowak May 1964 A
3282267 Wiliam Nov 1966 A
3502080 Hirschhorn Mar 1970 A
3587577 Smirnov et al. Jun 1971 A
3591645 Selwitz Jul 1971 A
3703897 Mack et al. Nov 1972 A
3710784 Taylor Jan 1973 A
3786814 Armao Jan 1974 A
3827436 Stumpf et al. Aug 1974 A
3942519 Shock Mar 1976 A
3948269 Zimmer Apr 1976 A
3986385 Johnston et al. Oct 1976 A
3993053 Grossan Nov 1976 A
4002221 Buchalter Jan 1977 A
4026299 Sauder May 1977 A
4140130 Storm, III Feb 1979 A
4149529 Copeland et al. Apr 1979 A
4178429 Scheffer Dec 1979 A
4202336 van Gerven et al. May 1980 A
4266043 Fujii et al. May 1981 A
4269068 Molina May 1981 A
4381009 Del Bon et al. Apr 1983 A
4396011 Mack et al. Aug 1983 A
4459854 Richardson et al. Jul 1984 A
4483341 Witteles Nov 1984 A
4528979 Marchenko et al. Jul 1985 A
4531524 Mioduski Jul 1985 A
4548212 Leung Oct 1985 A
4555313 Duchane et al. Nov 1985 A
4585002 Kissin Apr 1986 A
4603076 Bowditch et al. Jul 1986 A
4614191 Perler Sep 1986 A
4644955 Mioduski Feb 1987 A
4664110 Schanzlin May 1987 A
4700701 Montaldi Oct 1987 A
4718429 Smidt et al. Jan 1988 A
4741338 Miyamae et al. May 1988 A
4764463 Mason et al. Aug 1988 A
4802475 Weshahy et al. Feb 1989 A
4832022 Tjulkov et al. May 1989 A
4846176 Golden Jul 1989 A
4850340 Onishi Jul 1989 A
4869250 Bitterly Sep 1989 A
4880564 Abel et al. Nov 1989 A
4905697 Heggs et al. Mar 1990 A
4906463 Cleary et al. Mar 1990 A
4930317 Klein Jun 1990 A
4935345 Guilbeau et al. Jun 1990 A
4961422 Marchosky et al. Oct 1990 A
4962761 Golden Oct 1990 A
4990144 Blott Feb 1991 A
5007433 Hermsdorffer et al. Apr 1991 A
5018521 Campbell May 1991 A
5024650 Hagiwara et al. Jun 1991 A
5065752 Sessions et al. Nov 1991 A
5069208 Noppel et al. Dec 1991 A
5084671 Miyata et al. Jan 1992 A
5108390 Potocky et al. Apr 1992 A
5119674 Nielsen et al. Jun 1992 A
5139496 Hed et al. Aug 1992 A
5143063 Fellner Sep 1992 A
5148804 Hill et al. Sep 1992 A
5158070 Dory Oct 1992 A
5169384 Bosniak et al. Dec 1992 A
5197466 Marchosky et al. Mar 1993 A
5207674 Hamilton May 1993 A
5221726 Dabi et al. Jun 1993 A
5264234 Windhab et al. Nov 1993 A
5277030 Miller Jan 1994 A
5314423 Seney May 1994 A
5327886 Chiu Jul 1994 A
5330745 McDow Jul 1994 A
5333460 Lewis et al. Aug 1994 A
5334131 Omandam et al. Aug 1994 A
5336616 Livesey et al. Aug 1994 A
5339541 Owens Aug 1994 A
5342617 Gold Aug 1994 A
5351677 Kami et al. Oct 1994 A
5358467 Milstein et al. Oct 1994 A
5362966 Rosenthal et al. Nov 1994 A
5363347 Nguyen Nov 1994 A
5372608 Johnson Dec 1994 A
5386837 Sterzer Feb 1995 A
5411541 Bell et al. May 1995 A
5427772 Hagan Jun 1995 A
5433717 Rubinsky et al. Jul 1995 A
5456703 Beeuwkes, III Oct 1995 A
5472416 Blugerman et al. Dec 1995 A
5486207 Mahawili Jan 1996 A
5497596 Zatkulak Mar 1996 A
5501655 Rolt et al. Mar 1996 A
5505726 Meserol Apr 1996 A
5505730 Edwards Apr 1996 A
5507790 Weiss et al. Apr 1996 A
5514105 Goodman, Jr. et al. May 1996 A
5514170 Mauch May 1996 A
5531742 Barken Jul 1996 A
5562604 Yablon et al. Oct 1996 A
5571801 Segall et al. Nov 1996 A
5575812 Owens et al. Nov 1996 A
5603221 Maytal et al. Feb 1997 A
5628769 Saringer et al. May 1997 A
5634890 Morris Jun 1997 A
5634940 Panyard Jun 1997 A
5647051 Neer Jul 1997 A
5647868 Chinn Jul 1997 A
5650450 Lovette et al. Jul 1997 A
5651773 Perry et al. Jul 1997 A
5654279 Rubinsky et al. Aug 1997 A
5654546 Lindsay Aug 1997 A
5660836 Knowlton Aug 1997 A
5665053 Jacobs Sep 1997 A
5672172 Zupkas Sep 1997 A
5700284 Owens et al. Dec 1997 A
5725483 Podolsky Mar 1998 A
5733280 Avitall Mar 1998 A
5741248 Stern et al. Apr 1998 A
5746736 Tankovich May 1998 A
5755663 Larsen et al. May 1998 A
5755753 Knowlton May 1998 A
5755755 Panyard May 1998 A
5759182 Varney et al. Jun 1998 A
5759764 Polovina Jun 1998 A
5769879 Richards et al. Jun 1998 A
5785955 Fischer Jul 1998 A
5792080 Ookawa et al. Aug 1998 A
5800490 Patz et al. Sep 1998 A
5814040 Nelson et al. Sep 1998 A
5817050 Klein Oct 1998 A
5817149 Owens et al. Oct 1998 A
5817150 Owens et al. Oct 1998 A
5830208 Muller Nov 1998 A
5833685 Tortal et al. Nov 1998 A
5844013 Kenndoff et al. Dec 1998 A
5865841 Kolen et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5871526 Gibbs et al. Feb 1999 A
5885211 Eppstein et al. Mar 1999 A
5891617 Watson et al. Apr 1999 A
5895418 Saringer et al. Apr 1999 A
5901707 Gon.cedilla.alves et al. May 1999 A
5902256 Benaron May 1999 A
5919219 Knowlton Jul 1999 A
5944748 Mager et al. Aug 1999 A
5948011 Knowlton Sep 1999 A
5954680 Augustine et al. Sep 1999 A
5964092 Tozuka et al. Oct 1999 A
5964749 Eckhouse et al. Oct 1999 A
5967976 Larsen et al. Oct 1999 A
5980561 Kolen et al. Nov 1999 A
5986167 Arteman et al. Nov 1999 A
5989286 Owens et al. Nov 1999 A
5997530 Nelson et al. Dec 1999 A
6017337 Pira Jan 2000 A
6023932 Johnston Feb 2000 A
6032675 Rubinsky Mar 2000 A
6039694 Larson et al. Mar 2000 A
6041787 Rubinsky Mar 2000 A
6047215 McClure et al. Apr 2000 A
6049927 Thomas et al. Apr 2000 A
6051159 Hao Apr 2000 A
6071239 Cribbs et al. Jun 2000 A
6074415 Der Ovanesian Jun 2000 A
6093230 Johnson, III et al. Jul 2000 A
6102885 Bass Aug 2000 A
6104952 Tu et al. Aug 2000 A
6104959 Spertell et al. Aug 2000 A
6106517 Zupkas Aug 2000 A
6113558 Rosenschein et al. Sep 2000 A
6113559 Klopotek Sep 2000 A
6113626 Clifton et al. Sep 2000 A
6120519 Weber et al. Sep 2000 A
6139544 Mikus et al. Oct 2000 A
6150148 Nanda et al. Nov 2000 A
6152952 Owens et al. Nov 2000 A
6171301 Nelson et al. Jan 2001 B1
6180867 Hedengren et al. Jan 2001 B1
6226996 Weber et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6264649 Whitcroft et al. Jul 2001 B1
6273884 Altshuler et al. Aug 2001 B1
6290988 Van Vilsteren et al. Sep 2001 B1
6311090 Knowlton Oct 2001 B1
6311497 Chung Nov 2001 B1
6312453 Stefanile et al. Nov 2001 B1
6350276 Knowlton Feb 2002 B1
6354297 Eiseman Mar 2002 B1
6357907 Cleveland et al. Mar 2002 B1
6375673 Clifton et al. Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6401722 Krag Jun 2002 B1
6405090 Knowlton Jun 2002 B1
6413255 Stern Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6426445 Young et al. Jul 2002 B1
6430446 Knowlton Aug 2002 B1
6430956 Haas et al. Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6438954 Goetz et al. Aug 2002 B1
6438964 Giblin Aug 2002 B1
6453202 Knowlton Sep 2002 B1
6458888 Hood et al. Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6471693 Carroll et al. Oct 2002 B1
6475211 Chess et al. Nov 2002 B2
6478811 Dobak, III et al. Nov 2002 B1
6494844 Van Bladel et al. Dec 2002 B1
6497721 Ginsburg et al. Dec 2002 B2
6508831 Kushnir Jan 2003 B1
6514244 Pope et al. Feb 2003 B2
6519964 Bieberich Feb 2003 B2
6523354 Tolbert Feb 2003 B1
6527765 Kelman et al. Mar 2003 B2
6527798 Ginsburg et al. Mar 2003 B2
6544248 Bass Apr 2003 B1
6547811 Becker et al. Apr 2003 B1
6548297 Kuri-Harcuch et al. Apr 2003 B1
6551255 Van Bladel et al. Apr 2003 B2
6551341 Boylan et al. Apr 2003 B2
6551348 Blalock et al. Apr 2003 B1
6551349 Lasheras et al. Apr 2003 B2
6569189 Augustine et al. May 2003 B1
6585652 Lang et al. Jul 2003 B2
6592577 Abboud et al. Jul 2003 B2
6605080 Altshuler et al. Aug 2003 B1
6607498 Eshel Aug 2003 B2
6620187 Carson et al. Sep 2003 B2
6620188 Ginsburg et al. Sep 2003 B1
6620189 Machold et al. Sep 2003 B1
6623430 Slayton et al. Sep 2003 B1
6626854 Friedman et al. Sep 2003 B2
6632219 Baranov et al. Oct 2003 B1
6635053 Lalonde et al. Oct 2003 B1
6643535 Damasco et al. Nov 2003 B2
6645162 Friedman et al. Nov 2003 B2
6645229 Matsumura et al. Nov 2003 B2
6645232 Carson Nov 2003 B2
6648904 Altshuler et al. Nov 2003 B2
6656208 Grahn et al. Dec 2003 B2
6660027 Gruszecki et al. Dec 2003 B2
6662054 Kreindel et al. Dec 2003 B2
6682550 Clifton et al. Jan 2004 B2
6685731 Kushnir et al. Feb 2004 B2
6694170 Mikus et al. Feb 2004 B1
6695874 Machold et al. Feb 2004 B2
6697670 Chomenky et al. Feb 2004 B2
6699237 Weber et al. Mar 2004 B2
6699266 Lachenbruch et al. Mar 2004 B2
6699267 Voorhees et al. Mar 2004 B2
6718785 Bieberich Apr 2004 B2
6741895 Gafni et al. May 2004 B1
6743222 Durkin et al. Jun 2004 B2
6746474 Saadat Jun 2004 B2
6749624 Knowlton Jun 2004 B2
6764493 Weber et al. Jul 2004 B1
6764502 Bieberich Jul 2004 B2
6789545 Littrup et al. Sep 2004 B2
6795728 Chornenky et al. Sep 2004 B2
6820961 Johnson Nov 2004 B2
6821274 McHale et al. Nov 2004 B2
6840955 Ein Jan 2005 B2
6849075 Bertolero et al. Feb 2005 B2
6878144 Altshuler et al. Apr 2005 B2
6889090 Kreindel May 2005 B2
6892099 Jaafar et al. May 2005 B2
6904956 Noel Jun 2005 B2
6918903 Bass Jul 2005 B2
6927316 Faries, Jr. et al. Aug 2005 B1
6942022 Blangetti et al. Sep 2005 B2
6945942 Van Bladel et al. Sep 2005 B2
6948903 Ablabutyan et al. Sep 2005 B2
6969399 Schock et al. Nov 2005 B2
7005558 Johansson et al. Feb 2006 B1
7006874 Knowlton et al. Feb 2006 B2
7022121 Stern et al. Apr 2006 B2
7037326 Lee et al. May 2006 B2
7054685 Dimmer et al. May 2006 B2
7060061 Altshuler et al. Jun 2006 B2
7077858 Fletcher et al. Jul 2006 B2
7081111 Svaasand et al. Jul 2006 B2
7083612 Littrup et al. Aug 2006 B2
7096204 Chen et al. Aug 2006 B1
7112712 Ancell Sep 2006 B1
7115123 Knowlton et al. Oct 2006 B2
7141049 Stern et al. Nov 2006 B2
7183360 Daniel et al. Feb 2007 B2
7189252 Krueger Mar 2007 B2
7192426 Baust et al. Mar 2007 B2
7204832 Altshuler et al. Apr 2007 B2
7220778 Anderson et al. May 2007 B2
7229436 Stern et al. Jun 2007 B2
7258674 Cribbs et al. Aug 2007 B2
7267675 Stern et al. Sep 2007 B2
7276058 Altshuler et al. Oct 2007 B2
7318821 Lalonde et al. Jan 2008 B2
7331951 Eshel et al. Feb 2008 B2
7347855 Eshel et al. Mar 2008 B2
7367341 Anderson et al. May 2008 B2
7532201 Quistgaard et al. May 2009 B2
7572268 Babaev Aug 2009 B2
7604632 Howlett et al. Oct 2009 B2
7613523 Eggers et al. Nov 2009 B2
7615016 Barthe et al. Nov 2009 B2
7713266 Elkins et al. May 2010 B2
7780656 Tankovich Aug 2010 B2
7799018 Goulko Sep 2010 B2
7824437 Saunders Nov 2010 B1
7828831 Tanhehco et al. Nov 2010 B1
7850683 Elkins et al. Dec 2010 B2
7854754 Ting et al. Dec 2010 B2
7862558 Elkins et al. Jan 2011 B2
RE42277 Jaafar et al. Apr 2011 E
7938824 Chornenky et al. May 2011 B2
7963959 Da Silva et al. Jun 2011 B2
7967763 Deem et al. Jun 2011 B2
7993330 Goulko Aug 2011 B2
7998137 Elkins et al. Aug 2011 B2
RE42835 Chornenky et al. Oct 2011 E
RE43009 Chornenky et al. Dec 2011 E
8133180 Slayton et al. Mar 2012 B2
8133191 Rosenberg et al. Mar 2012 B2
8192474 Levinson Jun 2012 B2
8246611 Paithankar et al. Aug 2012 B2
8275442 Allison Sep 2012 B2
8285390 Levinson et al. Oct 2012 B2
8333700 Barthe et al. Dec 2012 B1
8337539 Ting et al. Dec 2012 B2
8366622 Slayton et al. Feb 2013 B2
8414631 Quisenberry et al. Apr 2013 B2
8433400 Prushinskaya et al. Apr 2013 B2
8506486 Slayton et al. Aug 2013 B2
8523775 Barthe et al. Sep 2013 B2
8523791 Castel Sep 2013 B2
8523927 Levinson et al. Sep 2013 B2
8535228 Slayton et al. Sep 2013 B2
8603073 Allison Dec 2013 B2
8636665 Slayton et al. Jan 2014 B2
8641622 Barthe et al. Feb 2014 B2
8663112 Slayton et al. Mar 2014 B2
8672848 Slayton et al. Mar 2014 B2
8676332 Fahey Mar 2014 B2
8690778 Slayton et al. Apr 2014 B2
8690779 Slayton et al. Apr 2014 B2
8690780 Slayton et al. Apr 2014 B2
8834547 Anderson et al. Sep 2014 B2
20010005791 Ginsburg et al. Jun 2001 A1
20010007952 Shimizu Jul 2001 A1
20010023364 Ahn Sep 2001 A1
20010031459 Fahy et al. Oct 2001 A1
20010039439 Elkins et al. Nov 2001 A1
20010045104 Bailey et al. Nov 2001 A1
20010047196 Ginsburg et al. Nov 2001 A1
20020026226 Ein Feb 2002 A1
20020032473 Kushnir et al. Mar 2002 A1
20020049483 Knowlton Apr 2002 A1
20020058975 Bieberich May 2002 A1
20020062142 Knowlton May 2002 A1
20020068338 Nanda et al. Jun 2002 A1
20020082668 Ingman Jun 2002 A1
20020103520 Latham Aug 2002 A1
20020107558 Clifton et al. Aug 2002 A1
20020117293 Campbell Aug 2002 A1
20020120315 Furuno et al. Aug 2002 A1
20020128648 Weber et al. Sep 2002 A1
20020151830 Kahn Oct 2002 A1
20020151887 Stern et al. Oct 2002 A1
20020156509 Cheung Oct 2002 A1
20020188286 Quijano et al. Dec 2002 A1
20020198518 Mikus et al. Dec 2002 A1
20030032900 Ella Feb 2003 A1
20030044764 Soane et al. Mar 2003 A1
20030055414 Altshuler et al. Mar 2003 A1
20030069618 Smith et al. Apr 2003 A1
20030077326 Newton et al. Apr 2003 A1
20030077329 Kipp et al. Apr 2003 A1
20030079488 Bieberich May 2003 A1
20030100936 Altshuler et al. May 2003 A1
20030109908 Lachenbruch et al. Jun 2003 A1
20030109910 Lachenbruch et al. Jun 2003 A1
20030109911 Lachenbruch et al. Jun 2003 A1
20030114885 Nova et al. Jun 2003 A1
20030120268 Bertolero et al. Jun 2003 A1
20030125649 McIntosh et al. Jul 2003 A1
20030187488 Kreindel et al. Oct 2003 A1
20030199226 Sommer et al. Oct 2003 A1
20030199859 Altshuler et al. Oct 2003 A1
20030220594 Halvorson et al. Nov 2003 A1
20030220635 Knowlton et al. Nov 2003 A1
20030220674 Anderson et al. Nov 2003 A1
20030236487 Knowlton Dec 2003 A1
20040002705 Knowlton et al. Jan 2004 A1
20040006328 Anderson Jan 2004 A1
20040009936 Tang et al. Jan 2004 A1
20040024437 Machold et al. Feb 2004 A1
20040030332 Knowlton et al. Feb 2004 A1
20040034341 Altshuler et al. Feb 2004 A1
20040039312 Hillstead et al. Feb 2004 A1
20040044384 Leber et al. Mar 2004 A1
20040049178 Abboud et al. Mar 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040074629 Noel Apr 2004 A1
20040077977 Ella et al. Apr 2004 A1
20040082886 Timpson Apr 2004 A1
20040093042 Altshuler et al. May 2004 A1
20040104012 Zhou et al. Jun 2004 A1
20040106867 Eshel et al. Jun 2004 A1
20040162596 Altshuler et al. Aug 2004 A1
20040176667 Mihai et al. Sep 2004 A1
20040186535 Knowlton Sep 2004 A1
20040199226 Shadduck Oct 2004 A1
20040206365 Knowlton Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040210287 Greene Oct 2004 A1
20040215294 Littrup et al. Oct 2004 A1
20040259855 Anderson et al. Dec 2004 A1
20040260209 Ella et al. Dec 2004 A1
20040260210 Ella et al. Dec 2004 A1
20040260211 Maalouf Dec 2004 A1
20050033957 Enokida Feb 2005 A1
20050049526 Baer Mar 2005 A1
20050049543 Anderson et al. Mar 2005 A1
20050049661 Koffroth Mar 2005 A1
20050113725 Masuda May 2005 A1
20050143781 Carbunaru et al. Jun 2005 A1
20050145372 Noel Jul 2005 A1
20050154314 Quistgaard Jul 2005 A1
20050154431 Quistgaard et al. Jul 2005 A1
20050159986 Breeland et al. Jul 2005 A1
20050182462 Chornenky et al. Aug 2005 A1
20050187495 Quistgaard et al. Aug 2005 A1
20050187597 Vanderschuit Aug 2005 A1
20050203446 Takashima Sep 2005 A1
20050215987 Slatkine Sep 2005 A1
20050222565 Manstein Oct 2005 A1
20050251117 Anderson et al. Nov 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20050261753 Littrup et al. Nov 2005 A1
20050283144 Shiono et al. Dec 2005 A1
20060030778 Mendlein et al. Feb 2006 A1
20060035380 Saint-Leger Feb 2006 A1
20060036300 Kreindel Feb 2006 A1
20060041704 Choi Feb 2006 A1
20060074313 Slayton et al. Apr 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060094988 Tosaya et al. May 2006 A1
20060106836 Masugi et al. May 2006 A1
20060122509 Desilets Jun 2006 A1
20060189964 Anderson et al. Aug 2006 A1
20060200063 Munro et al. Sep 2006 A1
20060206110 Knowlton et al. Sep 2006 A1
20060234899 Nekmard et al. Oct 2006 A1
20060259102 Slatkine Nov 2006 A1
20060265032 Hennings et al. Nov 2006 A1
20060270745 Hunt et al. Nov 2006 A1
20060293734 Scott et al. Dec 2006 A1
20070010811 Stern et al. Jan 2007 A1
20070010861 Anderson et al. Jan 2007 A1
20070032561 Lin et al. Feb 2007 A1
20070038156 Rosenberg Feb 2007 A1
20070055156 Desilets et al. Mar 2007 A1
20070055173 DeLonzor et al. Mar 2007 A1
20070055179 Deem et al. Mar 2007 A1
20070055180 Deem et al. Mar 2007 A1
20070055181 Deem et al. Mar 2007 A1
20070078502 Weber et al. Apr 2007 A1
20070100398 Sloan May 2007 A1
20070106342 Schumann May 2007 A1
20070129714 Elkins et al. Jun 2007 A1
20070135876 Weber Jun 2007 A1
20070141265 Thomson Jun 2007 A1
20070179482 Anderson Aug 2007 A1
20070198071 Ting et al. Aug 2007 A1
20070219540 Masotti et al. Sep 2007 A1
20070239075 Rosenberg et al. Oct 2007 A1
20070239150 Zvuloni et al. Oct 2007 A1
20070249519 Guha et al. Oct 2007 A1
20070255187 Branch Nov 2007 A1
20070255274 Stern et al. Nov 2007 A1
20070255362 Levinson et al. Nov 2007 A1
20070265585 Joshi et al. Nov 2007 A1
20070265614 Stern et al. Nov 2007 A1
20070270925 Levinson Nov 2007 A1
20070282249 Quisenberry et al. Dec 2007 A1
20070282318 Spooner et al. Dec 2007 A1
20080014627 Merchant et al. Jan 2008 A1
20080046047 Jacobs Feb 2008 A1
20080077201 Levinson et al. Mar 2008 A1
20080077202 Levinson Mar 2008 A1
20080077211 Levinson et al. Mar 2008 A1
20080139901 Altshuler et al. Jun 2008 A1
20080140061 Toubia et al. Jun 2008 A1
20080140371 Warner Jun 2008 A1
20080183164 Elkins et al. Jul 2008 A1
20080188915 Mills et al. Aug 2008 A1
20080248554 Merchant et al. Oct 2008 A1
20080269851 Deem et al. Oct 2008 A1
20080287839 Rosen et al. Nov 2008 A1
20080312651 Pope et al. Dec 2008 A1
20090012434 Anderson Jan 2009 A1
20090018623 Levinson et al. Jan 2009 A1
20090018624 Levinson et al. Jan 2009 A1
20090018625 Levinson et al. Jan 2009 A1
20090018626 Levinson et al. Jan 2009 A1
20090018627 Levinson et al. Jan 2009 A1
20090024023 Welches et al. Jan 2009 A1
20090076488 Welches et al. Mar 2009 A1
20090112134 Avni Apr 2009 A1
20090118722 Ebbers et al. May 2009 A1
20090149929 Levinson et al. Jun 2009 A1
20090149930 Schenck Jun 2009 A1
20090171253 Davenport Jul 2009 A1
20090171334 Elkins et al. Jul 2009 A1
20090221938 Rosenberg et al. Sep 2009 A1
20090276018 Brader Nov 2009 A1
20090281464 Cioanta et al. Nov 2009 A1
20090306749 Mulindwa Dec 2009 A1
20090312676 Rousso et al. Dec 2009 A1
20090312693 Thapliyal et al. Dec 2009 A1
20090326621 El-Galley Dec 2009 A1
20100015190 Hassler Jan 2010 A1
20100028969 Mueller et al. Feb 2010 A1
20100030306 Edelman et al. Feb 2010 A1
20100036295 Altshuler et al. Feb 2010 A1
20100049178 Deem et al. Feb 2010 A1
20100081971 Allison Apr 2010 A1
20100087806 Da Silva et al. Apr 2010 A1
20100152824 Allison Jun 2010 A1
20100168726 Brookman Jul 2010 A1
20100198064 Perl et al. Aug 2010 A1
20100268220 Johnson et al. Oct 2010 A1
20100280582 Baker et al. Nov 2010 A1
20110009860 Chornenky et al. Jan 2011 A1
20110040235 Castel Feb 2011 A1
20110040299 Kim et al. Feb 2011 A1
20110046523 Altshuler et al. Feb 2011 A1
20110060323 Baust et al. Mar 2011 A1
20110066083 Tosaya et al. Mar 2011 A1
20110066216 Ting et al. Mar 2011 A1
20110077557 Wing et al. Mar 2011 A1
20110077723 Parish et al. Mar 2011 A1
20110112405 Barthe et al. May 2011 A1
20110112520 Kreindel May 2011 A1
20110144631 Elkins et al. Jun 2011 A1
20110152849 Baust et al. Jun 2011 A1
20110172651 Altshuler et al. Jul 2011 A1
20110189129 Qiu et al. Aug 2011 A1
20110196395 Maschke Aug 2011 A1
20110196438 Mnozil et al. Aug 2011 A1
20110238050 Allison et al. Sep 2011 A1
20110238051 Levinson et al. Sep 2011 A1
20110257642 Griggs, III Oct 2011 A1
20110300079 Martens et al. Dec 2011 A1
20110301585 Goulko Dec 2011 A1
20110313411 Anderson et al. Dec 2011 A1
20110313412 Kim et al. Dec 2011 A1
20120010609 Deem et al. Jan 2012 A1
20120016239 Barthe et al. Jan 2012 A1
20120022518 Levinson Jan 2012 A1
20120022622 Johnson et al. Jan 2012 A1
20120035475 Barthe et al. Feb 2012 A1
20120035476 Barthe et al. Feb 2012 A1
20120046547 Barthe et al. Feb 2012 A1
20120053458 Barthe et al. Mar 2012 A1
20120065629 Elkins et al. Mar 2012 A1
20120083862 Altshuler et al. Apr 2012 A1
20120101549 Schumann Apr 2012 A1
20120109041 Munz May 2012 A1
20120158100 Schomacker Jun 2012 A1
20120209363 Williams, III et al. Aug 2012 A1
20120239123 Weber et al. Sep 2012 A1
20120253416 Erez et al. Oct 2012 A1
20120259322 Fourkas et al. Oct 2012 A1
20120277674 Clark, III et al. Nov 2012 A1
20120310232 Erez Dec 2012 A1
20130018236 Altshuler et al. Jan 2013 A1
20130019374 Schwartz Jan 2013 A1
20130066309 Levinson Mar 2013 A1
20130073017 Liu et al. Mar 2013 A1
20130079684 Rosen et al. Mar 2013 A1
20130116758 Levinson et al. May 2013 A1
20130116759 Levinson et al. May 2013 A1
20130150844 Deem et al. Jun 2013 A1
20130158636 Ting et al. Jun 2013 A1
20130166003 Johnson et al. Jun 2013 A1
20130185440 Blau et al. Jul 2013 A1
20130238062 Ron Edoute et al. Sep 2013 A1
20130245507 Khorassani Zadeh Sep 2013 A1
20130253384 Anderson et al. Sep 2013 A1
20130253493 Anderson et al. Sep 2013 A1
20130253494 Anderson et al. Sep 2013 A1
20130253495 Anderson et al. Sep 2013 A1
20130253496 Anderson et al. Sep 2013 A1
20130303904 Barthe et al. Nov 2013 A1
20130303905 Barthe et al. Nov 2013 A1
20130331914 Lee et al. Dec 2013 A1
20140005759 Fahey et al. Jan 2014 A1
20140005760 Levinson et al. Jan 2014 A1
20140142469 Britva et al. May 2014 A1
20140200488 Seo et al. Jul 2014 A1
20140277302 Weber et al. Sep 2014 A1
Foreign Referenced Citations (161)
Number Date Country
2011253768 Jun 2012 AU
2441489 Mar 2005 CA
2585214 Oct 2007 CA
333982 Nov 1958 CH
86200604 Oct 1987 CN
2514795 Oct 2002 CN
2514811 Oct 2002 CN
1511503 Jul 2004 CN
1741777 Mar 2006 CN
1817990 Aug 2006 CN
2843367 Dec 2006 CN
2850584 Dec 2006 CN
2850585 Dec 2006 CN
200970265 Nov 2007 CN
101259329 Sep 2008 CN
101309657 Nov 2008 CN
532976 Sep 1931 DE
2851602 Jun 1980 DE
2851602 Jun 1980 DE
4213584 Nov 1992 DE
4224595 Jan 1994 DE
4238291 May 1994 DE
4445627 Jun 1996 DE
19800416 Jul 1999 DE
0263069 Apr 1988 EP
0397043 Nov 1990 EP
0406244 Jan 1991 EP
0598824 Jun 1994 EP
1201266 May 2002 EP
1568395 Aug 2005 EP
2527005 Nov 2012 EP
854937 Apr 1940 FR
2744358 Aug 1997 FR
2745935 Sep 1997 FR
2767476 Feb 1999 FR
2776920 Oct 1999 FR
2789893 Aug 2000 FR
2805989 Sep 2001 FR
387960 Feb 1933 GB
2120944 Dec 1983 GB
2248183 Apr 1992 GB
2263872 Aug 1993 GB
2286660 Aug 1995 GB
2323659 Sep 1998 GB
58187454 Nov 1983 JP
63076895 Apr 1988 JP
S6382936 Apr 1988 JP
01223961 Sep 1989 JP
03051964 Mar 1991 JP
3259975 Nov 1991 JP
4093597 Mar 1992 JP
H06261933 Sep 1994 JP
6282977 Oct 1994 JP
7194666 Aug 1995 JP
7268274 Oct 1995 JP
09164163 Jun 1997 JP
10216169 Aug 1998 JP
10223961 Aug 1998 JP
2000503154 Mar 2000 JP
3065657 Jul 2000 JP
2001046416 Feb 2001 JP
2002125993 May 2002 JP
2002224051 Aug 2002 JP
2002282295 Oct 2002 JP
2002290397 Oct 2002 JP
2002543668 Dec 2002 JP
2003190201 Jul 2003 JP
2004013600 Jan 2004 JP
2004073812 Mar 2004 JP
2004073812 Mar 2004 JP
2005039790 Feb 2005 JP
3655820 Mar 2005 JP
200565984 Mar 2005 JP
2005110755 Apr 2005 JP
2005509977 Apr 2005 JP
2005520608 Jul 2005 JP
2005237908 Sep 2005 JP
2005323716 Nov 2005 JP
2008323716 Nov 2005 JP
2006026001 Feb 2006 JP
2006130055 May 2006 JP
2006520949 Sep 2006 JP
2007270459 Oct 2007 JP
2008532591 Aug 2008 JP
2009515232 Apr 2009 JP
2009189757 Aug 2009 JP
200173222 Dec 1999 KR
102004009450 Nov 2004 KR
20090000258 Jan 2009 KR
1020130043299 Apr 2013 KR
1020140038165 Mar 2014 KR
2036667 Jun 1995 RU
532976 Nov 1978 SU
0476644 Feb 2002 TW
WO-8503216 Aug 1985 WO
9114417 Oct 1991 WO
9404116 WO Mar 1994 WO
WO-9404116 Mar 1994 WO
9626693 Sep 1996 WO
WO-9636293 Nov 1996 WO
WO-9637158 Nov 1996 WO
9704832 Feb 1997 WO
WO-9705828 Feb 1997 WO
WO-9722262 Jun 1997 WO
9724088 Jul 1997 WO
WO-9725798 Jul 1997 WO
9748440 Dec 1997 WO
9829134 Jul 1998 WO
9831321 Jul 1998 WO
WO-9841157 Sep 1998 WO
WO-9841156 Sep 1998 WO
9909928 Mar 1999 WO
9916502 Apr 1999 WO
WO-9938469 Aug 1999 WO
0044349 Aug 2000 WO
WO-0044346 Aug 2000 WO
WO-0065770 Nov 2000 WO
WO-0067685 Nov 2000 WO
0100269 Jan 2001 WO
0113989 Mar 2001 WO
WO-0114012 Mar 2001 WO
WO-0205736 Jan 2002 WO
WO-02102921 Dec 2002 WO
0307859 Jan 2003 WO
WO-03078596 Sep 2003 WO
03079916 Oct 2003 WO
WO-2004000098 Dec 2003 WO
WO-2004080279 Sep 2004 WO
2004090939 Oct 2004 WO
WO-2005033957 Apr 2005 WO
WO-2005046540 May 2005 WO
2005060354 Jul 2005 WO
2005096979 Oct 2005 WO
2005112815 Dec 2005 WO
WO-2006066226 Jun 2006 WO
WO-2006094348 Sep 2006 WO
WO-2006106836 Oct 2006 WO
2006116603 Nov 2006 WO
WO-2006127467 Nov 2006 WO
WO-2007012083 Jan 2007 WO
2007028975 Mar 2007 WO
WO-2007041642 Apr 2007 WO
2007101039 Sep 2007 WO
WO-2007127924 Nov 2007 WO
2007145421 Dec 2007 WO
2007145422 Dec 2007 WO
2008006018 Jan 2008 WO
2008039556 Apr 2008 WO
WO-2008039557 Apr 2008 WO
2008055243 May 2008 WO
WO-2008143678 Nov 2008 WO
WO-2009011708 Jan 2009 WO
WO-2009026471 Feb 2009 WO
WO-2010077841 Jul 2010 WO
WO-2010127315 Nov 2010 WO
WO-2012012296 Jan 2012 WO
WO-2012103242 Aug 2012 WO
2013013059 Jan 2013 WO
2013075006 May 2013 WO
2013075016 May 2013 WO
2013190337 Dec 2013 WO
Non-Patent Literature Citations (152)
Entry
Ardevol, “Cooling rates of tissue samples during freezing with liquid nitrogen,” J. of Biochem and Biophysical Methods, 27, 77-86 (1993).
Bohm et al., “Saline-enhanced radiofrequency ablation of breast tissue: an in vitro feasibility study,” Invest Radiol, 2000, pp. 149-157, vol. 35—issue (3).
Bondei, E. et al., “Disorders of Subcutaneous Tissue (Cold Panniculitis),” Dermatology in General Medicine, Chapter 108, Section 16: 1333-1334, 1993.
Burge, S.M. et al., “Hair Follicle Destruction and Regeneration in Guinea Pig Skin after Cutaneous Freeze Injury,” Cryobiology, 27(2): 153-163, 1990.
Coban, “Ischemia-Reperfusion Injury of Adipofascial Tissue: An Experimental Study Evaluating early Histologic and Biochemical Alterations in Rats,” Mediators of Inflammation, 2005, 5, 304-308.
Donski et al., “The Effects of Cooling no Experimental Free Flap Survival,” Brit J Plas Surg, 1980, pp. 353-360, vol. 33.
Duncan, W.C. et al., “Cold Panniculitis,” Arch. Derm., 94:722-24, 1966.
Epstein, E.H. et al., “Popsicle Panniculitis,” The New England Journal of Medicine, 282(17):996-67, 1970.
European Search Report, European Application No. EP07758558.6; Applicant: Zeltiq Aesthetics, Inc.; dated Jul. 20, 2007, 4 pages.
European Search Report, European Patent Application No. 10167756.5, Applicant: The General Hospital Corporation, dated Aug. 31, 2010, 6 pages.
European Search Report, Eurpean Patent Application No. EP07761461; Applicant: Zeltiq Aesthetics, Inc., dated Apr. 25, 2012, 9 pages.
European Search Report, Supplement, European Patent Application No. EP08798416.7, Applicant: Zeltiq Aesthetics, Inc., dated Jan. 12, 2012, 7 pages.
European Search Report, Supplement, European Patent Application No. EP09836823, Applicant: Zeltiq Aesthetics, Inc., dated May 15, 2012, 5 pages.
Final Office Action; U.S. Appl. No. 10/391,221; dated Aug. 24, 2006, 4 pages.
Final Office Action; U.S. Appl. No. 11/016,196; dated Mar. 23, 2010, 12 pages.
Final Office Action; U.S. Appl. No. 11/435,502; dated Mar. 29, 2010, 11 pages.
Final Office Action; U.S. Appl. No. 11/528,225; dated Dec. 29, 2010, 9 pages.
Final Office Action; U.S. Appl. No. 11/558,046; dated Mar. 30, 2011, 17 pages.
Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 19, 2012, 8 pages.
Final Office Action; U.S. Appl. No. 11/750,953; dated Jul. 5, 2012, 11 pages.
Gage, “Current Progress in Cryosurgery,” Cryobiology 25, 483-486 (1988).
Hale et al., “Influence of chronic heat exposure and prolonged food deprivation on execretion of magnesium, phosphorus, calcium, hydrogen ion & ketones,” Aerosp Med, 1968, pp. 919-926, vol. 39—issue (9).
Heller-Page et al., “Temperature-dependent skin disorders,” Journal of the American Academy of Dermatology, May 1988, vol. 18, No. 5, Pt 1, pp. 1003-1019.
Hemmingsson, “Attenuation in Human muscle and Fat Tissue in Vivo and in Vitro,” Acta Radiologica Diagnosis 23, 149-151 (1982).
Henry et al.,“Les Dermatoses Hivernales,” Rev Med Liege, 1999, 54:11, 864-866. [Abstract Attached].
Holman, “Variation in cryolesion penetration due to probe size and tissue thermal conductivity,” Ann. Thorac. Surg. 53, 123-126 (1992).
Hong, “Patterns of Ice Formulation in Normal and Malignant Breast Tissue,” Cryobiology 31, 109-120 (1994).
International Search Report and Written Opinion for PCT/US2005/045988; Applicant: The General Hospital Corporation; dated Apr. 25, 2006, 14 pages.
International Search Report and Written Opinion for PCT/US2007/023492; Applicant: Zeltiq Aesthetics, Inc.; dated May 15, 2008, 7 pages.
International Search Report and Written Opinion for PCT/US2007/062508; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages.
International Search Report and Written Opinion for PCT/US2007/064016; Applicant: Juniper Medical, Inc.; dated Jul. 20, 2007, 13 pages.
International Search Report and Written Opinion for PCT/US2007/064017; Applicant: Juniper Medical, Inc.; dated Oct. 26, 2007, 16 pages.
International Search Report and Written Opinion for PCT/US2007/064018; Applicant: Juniper Medical, Inc.; dated Jul. 26, 2007, 13 pages.
International Search Report and Written Opinion for PCT/US2007/067638; Applicant: Juniper Medical, Inc.; dated Jan. 10, 2008, 11 pages.
International Search Report and Written Opinion for PCT/US2007/069694; Applicant: Juniper Medical, Inc.; dated Nov. 23, 2007, 12 pages.
International Search Report and Written Opinion for PCT/US2007/075935; Applicant: Zeltiq Aesthetics, Inc.; dated Apr. 10, 2008, 12 pages.
International Search Report and Written Opinion for PCT/US2007/083255; Applicant: Zeltiq Aesthetics, Inc.; dated Aug. 11, 2008, 8 pages.
International Search Report and Written Opinion for PCT/US2008/073930; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 7, 2008, 10 pages.
International Search Report and Written Opinion for PCT/US2009/058088; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 20, 2009, 14 pages.
International Search Report and Written Opinion for PCT/US2009/067973; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 18, 2010, 10 pages.
International Search Report and Written Opinion for PCT/US2010/033290; Applicant: Zeltiq Aesthetics, Inc.; dated Feb. 25, 2011, 12 pages.
International Search Report and Written Opinion for PCT/US2011/022112; Applicant: Zeltiq Aesthetics, Inc.; dated Mar. 18, 2011, 11 pages.
International Search Report and Written Opinion for PCT/US2011/022444; Applicant: Zeltiq Aesthetics, Inc., dated Mar. 29, 2011, 14 pages.
International Search Report and Written Opinion for PCT/US2012/022585; dated May 18, 2012, 14 pages.
Kellum, R.E. et al., “Sclerema Neonatorum: Report of Case and Analysis of Subcutaneous and Epidermal-Dermal Lipids by Chromatographic Methods,” Arch. Derm., 97:372-80, 1968.
Koska, J. et al., “Endocrine Regulation of Subcutaneous Fat Metabolism During Cold Exposure in Humans,” Ann N.Y. Acad, Sci., 967:500-05, 2002.
Kundu et al., “Breath acetone analyzer: diagnostic tool to monitor dietary fat loss,” Clin Chem, 1993, pp. 87-92, vol. 39, issue (1).
Kundu et al., “Novel solid-phase assay of ketone bodies in urine,” Clin Chem, 1991, pp. 1565-1569, vol. 37—issue (9).
Kuroda et al., “Thermal distribution of radio-frequency inductive hyperthermia using an inductive aperture-type applicator: evaluation of the effect of tumour size and depth,” Med Biol Eng Comput, 1999, pp. 285-290, vol. 37—issue (3).
Laugier, et al., “In Vivo Results with a New Device for Ultrasonic Monitoring of Pig Skin Cryosurgery: The Echographic Cryoprobe,” The society for Investigative Dermatology, Inc., vol. 111(2), Aug. 1998.
Levchenko, et al., “Effect of dehydration on lipid metabolism,” WMJ, 1978, pp. 95-97, vol. 50—issue (1).
Lidagoster, MD et al., “Comparison of Autologous Fat Transfer in Fresh, Refrigerated, and Frozen Specimens: An Animal Model Presented,” at the 16th Annual Meeting of the Northeastern Society of Plastic Surgeons: Burlington, VT, 1999, pp. 512-515.
Liu, A.Y.C. et al., “Transient Cold Shock Induces the Heat Shock Response upon Recovery at 37 C in Human Cells,” J. Biol. Chem., May 20, 1994, 269(20), 14768-14775.
Lvova, “Lipid levels and lipid peroxidation in frog tissues during hypothermia and hibernation,” WMJ, 1990, pp. 65-70, vol. 62—issue (1).
Maize, J.C., “Panniculitis,” Cutaneous Pathology, Chapter 13:327-344, 1998.
Malcolm, G. et al., “Fatty Acid Composition of Adipose Tissue in Humans: Differences between Subcutaneous Sites,” Am J Clin. Nutr., 50(2):288-91, 1989.
Merrill, Tom, “A Chill to the Heart: A System to Deliver Local Hypothermia Could One Day Improve the Lives of Heart-Attack Patients,” Mechanical Engineering Magazine, Oct. 2010 (10 pages).
Moschella, S.L. et al., “Diseases of the Subcutaneous Tissue,” Derm., Section 2:1169-1181, 1985.
Murphy, J.V. et al., “Frostbite: Pathogenesis and Treatment,” The Journal of Trauma: Injury, Infection, and Critical Care, 48(1):171-178, 2000.
Nagao et al., “ Dietary diacylglycerol suppresses accumulation of body fat compared to triacylglycerol in men a double-blind controlled trial,” J Nutr, 2000, pp. 792-797, vol. 130—issue (4).
Nagore et al., “Lipoatrophia semicircularis-a traumatic panniculitis: Report of seven cases and review of the literature,” Journal of the American Academy of Dermatology, Nov. 1998, 39:879-81.
Nielsen, “Thermoregulation in Rest and Exercise,” Acta Phys Scan Supp, 1969, pp. 6-74, vol. 323.
Nishikawa, “Ultrastructural Changes and Lipid Peroxidation in Rat Adipomusculocutaneous Flap Isotransplants after Normothermic Storage and Reperfusion,” Transplantation, 1992, 54, 795-801.
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jan. 25, 2006, 6 pages.
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated May 30, 2007, 8 pages.
Non-Final Office Action; U.S. Appl. No. 10/391,221; dated Jul. 22, 2005, 6 pages.
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Apr. 22, 2008, 11 pages.
Non-Final Office Action; U.S. Appl. No. 11/016,196; dated Sep. 25, 2009, 8 pages.
Non-Final Office Action; U.S. Appl. No. 11/359,092; dated Nov. 19, 2009, 13 pages.
Non-Final Office Action; U.S. Appl. No. 11/435,502; dated Jul. 17, 2009, 10 pages.
Non-Final Office Action; U.S. Appl. No. 11/528,189; dated Apr. 6, 2012, 9 pages.
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Apr. 12, 2010, 11 pages.
Non-Final Office Action; U.S. Appl. No. 11/528,225; dated Aug. 3, 2011, 11 pages.
Non-Final Office Action; U.S. Appl. No. 11/558,046; dated Jul 12, 2010, 14 pages.
Non-Final Office Action; U.S. Appl. No. 11/741,271; dated Jul. 12, 2010, 9 pages.
Non-Final Office Action; U.S. Appl. No. 11/777,992; dated Jun. 22, 2012, 5 pages.
Non-Final Office Action; U.S. Appl. No. 12/337,544; dated Mar. 30, 2012, 13 pgs.
Non-Final Office Action; U.S. Appl. No. 12/565,613; dated Sep. 23, 2011, 32 pages.
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Mar. 7, 2011, 6 pages.
Non-Final Office Action; U.S. Appl. No. 12/942,852; dated Jun. 30, 2011, 10 pages.
Pease, “An Integrated Probe for Magnetic Resonance Imaging Monitored Skin Cryosurgery,” Journal of Biomedical Engineering 117, 59-63, (1995).
Pech, “Attenuation values, volume changes and artifacts in tissue due to freezing,” Acta Radiologica 6, 779-782 (1987).
Peterson et al., “Bilateral Fat Necrosis of the Scrotum, Urology Service, Department of Surgery, Dermatology Service, Department of Medicine and Department of Pediatrics,” Letterman Army Medical Center, Journal of Urology, 1976, pp. 825-826, vol. 116, The Williams & Wilkins Co.
Phinney, S.D. et al., “Human Subcutaneous Adipose Tissue Shows Site-Specific Differences in Fatty Acid Composition,” Am J. Clin. Nutr., 60:725-29, 1994.
Pre-Interview Office Action; U.S. Appl. No. 11/434,478; dated May 6, 2010, 4 pages.
Rabi, “Metabolic adaptations in brown adipose tissue of the hamster in extreme ambient temperatures,” American Journal of Physiology 231, 153-160 (1976).
Renold, A.E., “Adipose Tissue,” Handbook of Physiology. Chapter 15:170-76, 1965.
Rubinsky, “Cryosurgery: advances in the application of low temperatures to medicine,” Int. J. Refrig. 190-199 (1991).
Schoning, et al., “Experimental Frostbite: Freezing Times, Rewarming Times, and Lowest Temperatures of Pig Skin Exposed to Chilled Air,” Cryobiology, 1990, pp. 189-193, 27.
Shephard, “Adaptation to Exercise in the Cold,” Sports Medicine, 1985, 2:59-71.
Wang et al., “Cryopreservation of cell/hydrogel constructs based on a new cell-assembling technique”, Sep. 5, 2009, 40 pages.
Wharton et al., “Cold acclimation and cryoprotectants in a freeze-tolerant Antarctic nematode, Panagrolaimus davidi,” Mar. 7, 2000, 2 pages.
Winkler et al., “Gene Transfer in Laboratory Fish: Model Organisms for the Analysis of Gene Function,” Transgenic Animals, 1997, pp. 387-395.
Young, H.E. et al., “Isolation of Embryonic Chick Myosatellite and Pluripotent Stem Cells, ” J. Tiss. Cult. Meth., 14:85-92, 1992.
U.S. Appl. No. 11/435,502, filed May 17, 2006, Levinson.
U.S. Appl. No. 11/528,189, filed Sep. 26, 2006, Levinson et al.
U.S. Appl. No. 11/528,225, filed Sep. 26, 2006, Levinson et al.
U.S. Appl. No. 11/741,271, filed Apr. 27, 2007, Levinson et al.
U.S. Appl. No. 11/750,953, filed May 18, 2007, Rosen et al.
U.S. Appl. No. 11/777,992, filed Jul. 13, 2007, Levinson et al.
U.S. Appl. No. 11/444,995, filed Jul. 13, 2007, Levinson et al.
U.S. Appl. No. 11/777,999, filed Jul. 13, 2007, Levinson et al.
U.S. Appl. No. 11/778,001, filed Jul. 13, 2007, Levinson et al.
U.S. Appl. No. 11/778,003, filed Jul. 13, 2007, Levinson et al.
U.S. Appl. No. 12/196,246, filed Jun. 11, 2009, Levinson.
U.S. Appl. No. 12/275,002, filed Nov. 20, 2008, Martens.
U.S. Appl. No. 12/275,014, filed Nov. 20, 2008, Martens.
U.S. Appl. No. 12/337,544, filed Jun. 17, 2010, Alison.
“Effect of Controlled Volumetric Tissue Heating with Radiorequency on Cellulite and the Subcutaneous Tissue of the Bottocks and Thighs” Del Pino, 2006, 9 pgs.
“So-Called Cellulite: An Invetnted Disease”, Nurnberger, Journal Title: Journal of dermatologic surgery and oncology, Mar. 1978, 14 pgs.
“ThermaCool Monopolar Capacitive Radiofrequency”,The one choice for nonabliative tissue tightening and contouring, Tech Brochure, Nov. 30, 2005, 8 pgs.
Aguilar et al., “Modeling Cryogenic Spray Temperature and Evaporation Rate Based on Single-Droplet Analysis”, Eighth International Conference on Liquid Atomization and Spray Systems, Pasadena, CA, USA, Jul. 2000, 7 pages.
Al-Sakere, “Tumor Ablation with Irreversible Electroporation”, Nov. 2007, Issue 11, 8 pgs.
Alster et el. “Cellulite treatment using a novel combination radiofrequency, infrared light, and mechanical tissue manipulation device,” J. of Cosmetic and Laser Therapy, vol. 7, 2005, p. 81-85.
Becker, “Local Tempertature Rises Influence in Vivo Electroporation Pore Development: A Numerical Stratum Corneum Lipid Phase Transition Model”, Oct. 2007, 10 pgs.
BioMedical Engineering OnLine, “High-Frequency Irreversible electroporation (H-FIRE) for non-thermal ablation without muscle contraction”, Nov. 21, 2011, 21 pgs.
Duck, Francis A., Physical Properties of Tissue, Academic Press Ltd., 1990, chapters 4 & 5, pp. 73-165.
European Search Report; Application No. EP10770461; Dated Aug. 31, 2012; Applicant: Zeltiq Aesthetics, Inc. 5 pgs.
European Search Report; Application No. EP14156801.4; Dated Aug. 22, 2014; Applicant: Zeltiq Aesthetics, Inc. 5 pgs.
Final Office Action, U.S. Appl. No. 13/013,579, dated Jun. 20, 2014, 15 pages.
Final Office Action; U.S. Appl. No. 13/013,603; dated Jul. 17, 2014, 17 pages.
Fournier et al. “Lattice model for the kinetics of rupture of fluid bilayer membranes,” Physical Review, vol. 67, 2003, 051908-1-051908-11.
Gabriel et al., “The dielectric properties of biological tissue: II. Measurements in the frequency range 10 Hz to 20 GHz,” Phys. Medical Biology, vol. 41, 1996, p. 2251-2269.
International Search Report and Written Opinion for PCT/US2011/044270; Applicant: Zeltiq Aesthetics, Inc.; dated Nov. 21, 2011. 9 pages.
International Search Report and Written Opinion for PCT/US2014/026556; dated Nov. 10, 2014, 16 pages.
International Search Report and Written Opinion for PCT/US2014/026558; dated Oct. 24, 2014, 16 pages.
Isambert “Understanding the Electroporation of Cells and Artificial Bilayer Membranes,” Phys. Review Letters, vol. 80, 1998, pp. 3404-3707.
Journal of Investigative Dermatology,“Comparative Proteomic Profiling of Murine Skin”, Chun-Ming Huang. Department of Dermatology, VH-501.
Manstein et al. “A Novel Cryotherapy Method of Non-invasive, Selective Lipolysis” LasersSurg.Med 40:S20 p. 104 (2008).
Manstein et al.“Selective Cryolysis: A Novel Method of Non-Invasive Fat Removal”, LasersSurg.Med. 40:595-604 (2008).
Mayoral, “Skin Tightening with a Combinded Unipolar and Bipolar Radiofrequency Device” , 2007 Journal of Drugs in Dermatology, 4 pgs.
Mazur, P. “Cryobiology: the Freezing of Biological Systems” Science, 68: 939-949 (1970).
Miklavcic, “Electroporation-Based Technologies and Treatments”, 2010 236:1-2, 2 pgs.
Nagle W.A., Soloff, B.L., Moss, A.J. Jr., Henle K.J. “Cultured Chinese Hamster Cells Undergo Apoptosis After Exposure to Cold but Nonfreezing Temperatures” Cryobiology 27, 439-451 (1990).
Nanda, “Studies on electroporation of thermally and chemically treated human erythocytes”, May 28, 1993 in revised form Mar. 7, 1994, 6 pgs.
Narins,“Non-Surgical Radiofrequency Facelift”, 2003, 495-500, 6 pgs.
Non-Final Office Action, U.S. Appl. No. 13/616,497, dated Jun. 28, 2013, 38 pages.
Non-Final Office Action; U.S. Appl. No. 12/840,235; dated Apr. 11, 2013; 9 pages.
Nurnberger, Editorial Comment to the Papers on “Cellulite”, 220-229, 9 pgs.
Pierard et al. “Cellulite: From Standing Fat Herniation to Hypodermal Stretch Marks,” Am. J. Dermatol. 22:1, 34-37, 2000.
Pope, “Selective Firbous Septae Heating”, Thermage Article, Feb. 2005, 7pgs.
PubMed, “Cold shock induces the synthesis of stress proteins in human kerantinocytes”, Holland DB. Aug. 1993; 101(2): 196-9.
PubMed, “Effects of thermal shocks on interleukin-1 levels and heat shock protein 72 (HSP72) expression in normal human keratinocytes”, Arch Dermatol Res. 1992; 284(7): 414-7.
Quinn, “A Lipid Phase Separation Model of Low Temperature Damage to Biological Membranes” Cryobiology, 22: 128-147, 1985.
Rossi, “Cellulite: a Review” 2000, 251-262, 12 pgs.
Rubinsky, B., “Principles of Low Temperature Preservation” Heart Failure Reviews, 8, 277-284 (2003).
Saleh et el. “Two-dimensional ultrasound phased array design for tissue ablation for treatment of benign hyperplasia,” Int. J. Hyperthermia, vol. 20, No. 1, Feb. 2004, p. 7-31.
Sigma-Aldrich “Polyethylene glycol and Polyethylene oxide,” http://www.sigmaaldrich.com/materials-science/materialscience-; products.htmi?TablePage=20204110 0, accessed Oct. 19, 2012.
Smalls, “Quantitative Model of Cellulite: Three Dimensional Skin Surgace Topography, Biophsical Characterization and Relationship to Human Perception”, 17 pgs.
Thermage, News Release, “Study Published in Facial Plastic Surgery Journal Finds Selective Heating of Fibrous Septae Key to Success and Safety of Thermage ThermoCool System”, Jun. 20, 2005, 2 pages.
Vallerand, A.L., Zamecnik. J., Jones, P.J.H. Jacobs, I. “Cold Stress Increases Lipolysis, FFA RA and TG/FFA Cycling in Humans” Aviation, Space, and Environmental Medicine 70, 4250 (1999).
Zouboulis et al., “Current Developments and Users of Cryosurgery in the Treatment of Keloids and Herpertrophic Scars”, Wound Repair and Regeneration, vol. 10, No. 2, pp. 98-102, 2002.
Related Publications (1)
Number Date Country
20110238051 A1 Sep 2011 US
Provisional Applications (2)
Number Date Country
61298175 Jan 2010 US
61354615 Jun 2010 US